EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF); Scientific Opinion on Flavouring Group Evaluation 17, Revision 3 (FGE.17Rev3): Pyrazine derivatives from chemical group 24 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 19, 2017
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
(CEF); Scientific Opinion on Flavouring Group Evaluation 17, Revision 3 (FGE.17Rev3):
Pyrazine derivatives from chemical group 24
EFSA Publication; Larsen, John Christian; Nørby, Karin Kristiane; Beltoft, Vibe Meister; Lund, Pia;
Binderup, Mona-Lise; Frandsen, Henrik Lauritz
Link to article, DOI:
10.2903/j.efsa.2011.2456
Publication date:
2011
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2011). EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
(CEF); Scientific Opinion on Flavouring Group Evaluation 17, Revision 3 (FGE.17Rev3): Pyrazine derivatives
from chemical group 24. Parma, Italy: European Food Safety Authority.  (The EFSA Journal; No. 2456). DOI:
10.2903/j.efsa.2011.2456
  EFSA Journal 2011; 9(11):2456
 
Suggested citation: EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF); Scientific 
Opinion on Flavouring Group Evaluation 17, Revision 3 (FGE.17Rev3): 
Pyrazine derivatives from chemical group 24. EFSA Journal 2011; 9(11):2456. [67 pp.]. doi:10.2903/j.efsa.2011.2456. 
Available online: www.efsa.europa.eu/efsajournal.htm  
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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 17, Revision 3 
(FGE.17Rev3): 
Pyrazine derivatives from chemical group 241 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 28 flavouring substances in the Flavouring Group 
Evaluation 17, including seven additional substances considered in this Revision 3, using the 
Procedure in Commission Regulation (EC) No 1565/2000. From the in vitro data available, genotoxic 
potential is indicated for the flavouring substances quinoxaline [FL-no: 14.147] and 2-
methylquinoxaline [FL-no: 14.139]. Therefore, the Panel decided that the Procedure could not be 
applied to these two substances, until adequate data showing absence of genotoxicity are provided. For 
one substance [FL-no: 14.051] no intake data are available preventing it from being evaluated through 
the Procedure. The remaining 25 substances were evaluated through a stepwise approach that 
integrates information on structure-activity relationships, intake from current uses, toxicological 
threshold of concern, and available data on metabolism and toxicity. The Panel concluded that 24 
substances [FL-no: 14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 14.099, 14.101, 
14.102, 14.108, 14.109, 14.111, 14.112, 14.113, 14.122, 14.126, 14.127, 14.128, 14.129, 14.148, 
14.161 and 14.170] do not give rise to safety concerns at their levels of dietary intake, estimated on the 
basis of the MSDI approach. For the remaining substance [FL-no: 14.052], additional toxicity data are 
required. Besides the safety assessment of these flavouring substances, the specifications for the 
materials of commerce have also been considered and for one substance [FL-no: 14.102], the 
composition of mixture has not been specified sufficiently.  
© European Food Safety Authority, 2011 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 28 flavouring substances in the 
Flavouring Group Evaluation 17, Revision 3 (FGE.17Rev3), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 28 flavouring substances belong to chemical 
group 24 of Annex I of the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation (FGE) deals with 28 pyrazine derivatives. Three of these 
derivatives are quinoxalines. 
Five flavouring substances possess one or two chiral centres. For all five substances, the 
stereoisomeric composition has been specified. 
Twenty flavouring substances are classified into structural class II and eight are classified into 
structural class III. 
Twenty-four of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intakes” (MSDIs) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the flavouring substances in this group, which are evaluated 
through the Procedure and for which Industry has provided intake data, have intakes in Europe from 
0.0024 to 12 microgram/capita/day, which are below the threshold of concern value for both structural 
class II (540 microgram/person/day) and structural class III (90 microgram/person/day) substances. 
For one candidate substance [FL-no: 14.051], no intake data are available, preventing it from being 
evaluated through the Procedure. 
From the in vitro data available, a genotoxic potential is indicated for quinoxaline [FL-no: 14.147] and 
2-methylquinoxaline [FL-no: 14.139]. Therefore, the Panel decided that the Procedure could not be 
applied to these two substances until adequate genotoxicity data become available. 
No genotoxic potential at gene or chromosome level is indicated for 2,3-dimethylquinoxaline [FL-no: 
14.108] and the remaining alkyl- and cycloalkyl-substituted pyrazines, which allows these substances 
to be evaluated through the Procedure.  
So, in total, 25 substances are evaluated through the Procedure, based on the MSDI approach 
Appendix I). 
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Twenty-two of the alkyl- and cycloalkyl-substituted pyrazines and one of the alkyl-substituted 
quinoxalines may be expected to be metabolised to innocuous products [FL-no: 14.051, 14.057, 
14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 14.099, 14.101, 14.102, 14.108, 14.109, 
14.111, 14.112, 14.113, 14.126, 14.127, 14.129, 14.148, 14.161 and 14.170]. Regarding the remaining 
five substances, they cannot be anticipated to be metabolised to innocuous products. Two sulphur-
containing flavouring substance [FL-no: 14.122 and 14.128], may be converted to a reactive free thiol. 
It can also not be assumed that quinoxaline [FL-no: 14.147] and its derivative 2-methylquinoxaline 
[FL-no: 14.139] are metabolised to innocuous products. The fifth substance [FL-no: 14.052] has a 
terminal double bond in conjugation with a heterocyclic aromatic ring, which may be epoxidised 
giving rise to reactive metabolites. 
It was noted, that where toxicity data were available they were consistent with the conclusions in the 
present FGE. 
It was considered that on the basis of the default MSDI approach, the 24 of the 25 flavouring 
substances evaluated through the Procedure would not give rise to safety concerns at the estimated 
levels of intake arising from their use as flavouring substances. No valid toxicity study from which a 
NOAEL could be established was available for isopropenylpyrazine [FL-no: 14.052] or for any 
relevant supporting substance. Therefore, the Panel concluded that additional toxicity data are needed 
for this substance. 
When the estimated intakes, of the substances evaluated through the Procedure, were based on the 
mTAMDI approach they ranged from 190 to 1100 microgram/person/day for the 17 flavouring 
substances from structural class II for which data have been provided. These intakes were below the 
threshold of concern for structural class II of 540 microgram/person/day, except for one substance 
[FL-no: 14.170]. The estimated intake of the two flavouring substances [FL-no: 14.108 and 14.122] 
assigned to structural class III for which data have been provided, and evaluated through the 
Procedure, are 190 and 270 microgram/person/day, respectively, which are above the threshold of 
concern for structural class III of 90 microgram/person/day. The 16 substances, which have mTAMDI 
intake estimates below the threshold of concern for structural class II, are also expected to be 
metabolised to innocuous products. Thus, for three flavouring substances [FL-no: 14.108, 14.122 and 
14.170] the intakes estimated on the basis of the mTAMDI, exceed the relevant threshold for their 
structural class, to which the flavouring substance has been assigned. For seven substances [FL-no: 
14.051, 14.057, 14.109, 14.111, 14.112, 14.126 and 14.128], no use levels were provided. Therefore, 
for these 10 substances more reliable exposure data are required. On the basis of such additional data, 
the flavouring substances should be re-evaluated using the Procedure. Subsequently, additional 
toxicity data might become necessary. 
Thus, in conclusion, 25 of the 28 flavouring substances were evaluated through the Procedure (based 
on MSDI approach), as two flavouring substances, quinoxaline [FL-no: 14.147] and 2-
methylquinoxaline [FL-no: 14.139] could not be evaluated through the Procedure until adequate 
genotoxicity data become available and one substance [FL-no: 14.051] was presented with no intake 
data and therefore could not be evaluated through the Procedure.  
In order to determine whether the conclusion for the 25 flavouring substances which have been 
evaluated using the Procedure (MSDI approach) can be applied to the materials of commerce, it is 
necessary to consider the available specifications. Adequate specifications including purity criteria and 
identity for the materials of commerce have been provided for 24 flavouring substances evaluated 
through the Procedure. For the substance [FL-no: 14.102], the final evaluation of the materials of 
commerce cannot be performed pending further information on composition of mixture of positional 
isomers.  
For one substance [FL-no: 14.052] evaluated through the Procedure, additional toxicity data are 
required. 
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For the remaining 23 substances [FL-no: 14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 
14.097, 14.099, 14.101, 14.108, 14.109, 14.111, 14.112, 14.113, 14.122, 14.126, 14.127, 14.128, 
14.129, 14.148, 14.161 and 14.170] the Panel concluded that they would present no safety concern at 
the level of intake estimated on the basis of the MSDI approach.  
KEYWORDS 
Flavourings, pyrazine, quinoxaline, food safety, FGE.17, FGE.50Rev1. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
In previous revisions of the present FGE, it was found that two of the candidate substances, 
quinoxaline [FL-no: 14.147] and 2-methylquinoxaline [FL-no: 14.139] showed a possible genotoxic 
potential in vitro and accordingly the Procedure could not be applied to these two candidate substances 
nor for the structurally related 2,3-dimethylquinoxaline [FL-no: 14.108] until adequate genotoxicity 
data became available.  
Additional genotoxicity data have become available for the structurally related supporting substance 
5-methylquinoxaline [FL-no: 14.028] (evaluated in FGE.50) and in FGE.17Rev2 these genotoxicity 
data submitted by the Industry (Flavour Industry, 2009a) have been evaluated. The available data 
indicate that there is no apparent structure-activity relationship for the genotoxicity of quinoxalines 
(Hashimoto et al., 1979). Therefore these compounds [FL-no; 14.139 and 14.147] are to be evaluated 
based on substance-specific data for each individual quinoxaline derivative. 
The revision 2 of FGE.17 also included the evaluation of one new substance [FL-no: 14.051]. [FL-no: 
14.051] is one isomer of the mixture of the structural isomers of [FL-no: 14.077] (see Table 1 and 
Table 3, respectively). The Panel decided that the evaluation of [FL-no: 14.077] could not cover [FL-
no: 14.051] and accordingly the evaluation of [FL-no: 14.051] was included in FGE.17Rev2. No 
European production figure for this substance is available. 
FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.17 7 December 2005 http://www.efsa.eu.int/science/afc/afc_opinions/1291_en.html 18 
FGE.17Rev1 30 January 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902101869.htm 
20 
FGE.17Rev2 
 
23 November 2010 http://www.efsa.europa.eu/en/efsajournal/pub/1920.htm 21 
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FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.17Rev3 23 November 2011  28 
 
The present revision of FGE.17, FGE.17Rev3, includes the assessment of seven additional candidate 
substances [FL-no: 14.057, 14.109, 14.111, 14.112, 14.126, 14.128 and 14.170]. No toxicity or 
metabolism data were provided for the new substances. A search in open literature provided no further 
data on toxicity or metabolism for the substances. 
 
Furthermore, new information from Industry on missing stereoisomeric composition for [FL-no: 
14.099 and 14.102] received after publication of the last revision is included in the present revision 
(EFFA, 2011a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), prior to their authorisation and inclusion in the Union list 
(Regulation (EC)  No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
In a letter of 1 April 2009 the Commission requested EFSA to carry out a re-evaluation of flavouring 
substances [FL-no: 14.028, 14.108 and 14.139] in accordance with Commission Regulation (EC) No 
1565/2000. This re-evaluation was made in FGE.17Rev2. 
After the finalisation of the evaluation programme, in their letter of the 30th July 2010, the 
Commission requested EFSA to carry out an evaluation of the flavouring substance 5-ethyl 2,3-
dimethyl pyrazine [FL-no: 14.170], also according to Commission Regulation (EC) No 1565/2000 
(EC, 2000a). 
In addition, in letter of 22 September 2011, the Commission has asked EFSA to reflect newly 
requested information on specifications in the revisions of FGEs. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 17, Revision 3 
1.1. Description 
The present revision of Flavouring Group Evaluation 17, FGE.17Rev3, using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in 
schematic form in Annex I of this FGE), deals with 28 pyrazine derivatives (candidate substances), 
which belong to chemical group 24 of Annex I of Commission Regulation (EC) No 1565/2000 (EC, 
2000a). 
The candidate substances under consideration, as well as their chemical Register names, FLAVIS- 
(FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufacturers Association- (FEMA-) numbers, structure and specifications, are listed in Table 1.  
All the candidate substances contain a pyrazine moiety. In 20 substances [FL-no: 14.051, 14.052, 
14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 14.101, 14.109, 14.111, 14.112, 
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14.122, 14.126, 14.127, 14.128, 14.129 and 14.170] only one heterocyclic ring is present. In five 
candidate substances a pyrazine ring is fused with either cyclopentane [FL-no: 14.099, 14.102, 14.113 
and 14.161] or with cyclohexane [FL-no: 14.148]. All of these 25 substances have different ring 
substituents. In 16 substances, the substituents are simple alkyl chains and/or ketones. In nine 
substances, the substituents are, next to alkyl chains, either a methoxy- ([FL-no: 14.051, 14.057, 
14.112, 14.126 and 14.127], an ethoxy- [FL-no: 14.109], a thiomethyl- [FL-no: 14.122 and 14.128]) or 
an isopropenyl residue [FL-no: 14.052]. In the remaining three candidate substances the pyrazine ring 
is fused with benzene giving quinoxalines. In two of the quinoxalines [FL-no: 14.108 and 14.139] the 
pyrazine ring also bears one or two methyl substituents; in the third no substituents are present 
(quinoxaline; [FL-no: 14.147]).  
A summary of the outcome of the safety evaluation of the candidate substances is listed in Table 2. 
The candidate substances are structurally related to 41 flavouring substances (supporting substances) 
evaluated at the 57th JECFA meeting in the group “Pyrazine Derivatives” (JECFA, 2002b). The name 
and structures of the 41 supporting substances are listed in Table 3, together with their evaluation 
status (JECFA. 2002b; SCF,1992). 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Five of the flavouring substances possess one or two chiral centres [FL-no: 14.099, 14.102, 14.113, 
14.148 and 14.161].  For all five substances, the stereoisomeric composition has been specified. 
1.3. Natural Occurrence in Food 
Twenty-four of the candidate substances have been reported to occur in beef, chicken, cocoa, coffee, 
green tea, fruit juice, beer, potato, pork, whisky, sherry, nuts, peanut, roasted sesame seed, peas, malt 
or wild rice. Quantitative data on the natural occurrence in food have been reported for 10 of these 
substances (TNO, 2000; TNO, 2011). 
These reports are: 
• Isopropenylpyrazine [FL-no: 14.052]: 0.11 mg/kg in malt. 
• 2-Isopropyl-3-methoxypyrazine [FL-no: 14.057]: up to 0.09 mg/kg in coffee, up to 0.006 
mg/kg in wine, up to 0.0001 mg/kg in potato and 0.00001 mg/kg in peas. 
• 2-Acetyl-5-methylpyrazine [FL-no: 14.084]: up to 0.3 mg/kg in coffee. 
• 2-Acetyl-6-methylpyrazine [FL-no: 14.087]: up to 0.55 mg/kg in coffee. 
• 2-Butyl-3-methylpyrazine [FL-no: 14.091]: 1 mg/kg in cocoa. 
• 2,5-Diethylpyrazine [FL-no: 14.097]: up to 0.1 mg/kg in coffee, and 0.02 mg/kg in peanut. 
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• 3-Ethyl-2,5-dimethylpyrazine [FL-no: 14.111]: up to 2.8 mg/kg in cocoa, up to 2.2 mg/kg in 
coffee, up to 12.5 mg/kg in pork, 2.2 mg/kg in potato chips, up to 0.4 mg/kg in malt, up to 0.3 
mg/kg in shrimps and soybean, 0.2 mg/kg in tea, 0.2 mg/kg in rum, 0.1 mg/kg in peanut, up to 
0.02 mg/kg in beer, up to 0.013 mg/kg in maize and beef,  
• Quinoxaline [FL-no: 14.147]: up to 0.1 mg/kg in malt. 
• 6,7-Dihydro-2,5-dimethyl-5H-cyclopentapyrazine [FL-no: 14.161]: up to 5.1 mg/kg in coffee, 
and up to 0.0001 mg/kg in pork. 
• 5-Ethyl-2,3-dimethyl pyrazine [FL-no: 14.170]: 10 mg/kg in coffee, up to 4 mg/kg in coconut, 
0.3 mg/kg in potato chips, up to 0.2 mg/kg in cocoa and up to 0.01 mg/kg in malt. 
According to TNO, four of the candidate substances, 2-, 5- or 6-methoxy-3-ethylpyrazine, 2-ethoxy-3-
methylpyrazine 2-isopropyl-3-methylthiopyrazine and 2-methyl-3-methylthiopyrazine [FL-no: 
14.051,14.109 14.122 and 14.128], have not been reported to occur naturally in any food items (TNO, 
2000; TNO, 2009; TNO, 2011). 
2. Specifications 
Purity criteria for 27 of the candidate substances have been provided by the Flavouring Industry 
(EFFA, 2003q; EFFA, 2007e; EFFA, 2007f; Flavour Industry, 2010m; EFFA, 2011e). For one 
substance [FL-no: 14.051] no purity criteria has been provided. 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), this information is adequate for the 27 of the candidate substances. Specifications are lacking 
for [FL-no: 14.051].  
However, according to Industry (EFFA, 2007e; EFFA, 2011a) [FL-no: 14.102] covers a mixture of 
2,5-dimethyl-6,7-dihydro-5H-cyclopentapyrazine (60 - 100 %) and 3,5-dimethyl-6,7-dihydro-5H-
cyclopentapyrazine (30 - 60 %). The composition of this mixture has to be further specified (Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
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beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the FGE.17Rev3 the total annual volume of production for 27 candidate substances from use as 
flavouring substances in Europe has been reported to be approximately 130 kg (EFFA, 2003r; EFFA, 
2007e; EFFA, 2007f; Flavour Industry, 2010m; EFFA, 2011e). For one substance [FL-no: 14.051] no 
annual volumes of production in Europe have been submitted. For the 41 supporting substances the 
total annual volume of production is approximately 2700 kg. About 65 % of the total annual volume 
of production in Europe is accounted for by 2,3,5-trimethylpyrazine [FL-no: 14.019], 2-ethyl-3-
methylpyrazine [FL-no: 14.006] and 3,(5- or 6-)-dimethyl-2-ethylpyrazine [FL-no: 14.100] (JECFA, 
2002b). 
On the basis of the annual volumes of production reported for the candidate substances, the daily per 
capita intakes for each of these flavourings have been estimated (Table 2). Approximately 70 % of the 
total annual volume of production for the candidate substances (EFFA, 2003r; EFFA, 2011e) is 
accounted for by the candidate substance 2-methoxy-3-methylpyrazine [FL-no: 14.126]. The estimated 
daily per capita intake of this candidate substance from use as flavouring substances is 12 microgram, 
and below 2.1 microgram for each of the remaining candidate substances (Table 2). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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For the present evaluation of the candidate substances information on food categories and normal and 
maximum use levels5,6,7 were submitted by the Flavour Industry for 21 substances (EFFA, 2003q; 
EFFA, 2007a; EFFA, 2007e; EFFA, 2007f; Flavour Industry, 2010m). No information on use levels 
have been submitted for [FL-no: 14.051, 14.057, 14.109, 14.111, 14.112, 14.126 and 14.128]. The 21 
candidate substances are used in flavoured food products divided into the food categories, outlined in 
Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For 
the present calculation of mTAMDI, the reported normal use levels were used. In the case where 
different use levels were reported for different food categories the highest reported normal use level 
was used.  
Table 3.1 Use of Candidate Substances in Various Food Categories for 21 Candidate Substances for 
which Data on Use have been provided. 
Food 
category 
Description Flavourings used* 
01.0 Dairy products, excluding products of category 2 All 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-
no:14.170] 
03.0 Edible ices, including sherbet and sorbet All 
04.1 Processed fruits All except [FL-
no:14.170] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
None 
05.0 Confectionery All 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
All except [FL-
no:14.170] 
07.0 Bakery wares All except [FL-no: 
14.099 & 14.101] 
08.0 Meat and meat products, including poultry and game All 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-
no:14.170] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-
no:14.170] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-
no:14.170] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All 
15.0 Ready-to-eat savouries All except [FL-
no:14.170] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
All except [FL-
no:14.170] 
* No use levels have been submitted for [FL-no: 14.051, 14.057, 14.109, 14.111, 14.112, 14.126 and 14.128]. 
According to the Flavour Industry the normal use levels for the candidate substances for which intake 
data are available are in the range of 0.1 - 3.13 mg/kg food, and the maximum use levels are in the 
range of 0.4 - 10 mg/kg (EFFA, 2003q; EFFA, 2007a; EFFA, 2007e; EFFA, 2007f; Flavour Industry, 
2010m) Table II.1.2, Appendix II.  
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile 
of reported usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from 
figures derived from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 
14.2 “Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 
2007a). 
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The mTAMDI values for the 17 candidate substances from structural class II (see Section 5) for which 
use levels are available range from 190 to 1100 microgram/person/day. For the remaining four 
candidate substances from structural class III the mTAMDI range from 190 to 270 
microgram/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
A more detailed description of the metabolism of the 28 candidate substances in this FGE is given in 
Annex III. 
This group of flavouring substances consists of candidate substances, all containing a pyrazine ring.  
In 20 substances [FL-no: 14.051, 14.052, 14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 
14.097, 14.101, 14.109, 14.111, 14.112, 14.122, 14.126, 14.127, 14.128, 14.129 and 14.170] only one 
heterocyclic ring is present. In five candidate substances a pyrazine ring is fused with either 
cyclopentane [FL-no: 14.099, 14.102, 14.113 and 14.161] or with cyclohexane [FL-no: 14.148]. All of 
these 25 substances have different substituents on the rings. In 16 of them, the substituents are simple 
alkyl chains and / or ketones. In nine, the substituents are, next to alkyl chains, either a methoxy- ([FL-
no: 14.051, 14.057, 14.112, 14.126 and 14.127], an ethoxy- [FL-no: 14.109], a thiomethyl- [FL-no: 
14.122 and 14.128]) or an isopropenyl residue [FL-no: 14.052].  
In the remaining three candidate substances the pyrazine ring is fused with benzene giving 
quinoxalines. In two of these substances [FL-no: 14.139 and 14.108] the pyrazine ring also bears one 
or two methyl substituents and in the third no substituents are present (quinoxaline [FL-no 14.147]).  
A group with 41 related supporting substances has been evaluated by the JECFA (JECFA, 2002a). 
Very little data on absorption, distribution and elimination of the candidate or supporting flavouring 
substances are available. The available data indicate that the weak basic heterocyclic substances in this 
group may be well absorbed, mainly from the intestinal lumen, and may be rapidly excreted. 
Limited information has been submitted to describe the metabolism of the pyrazines and alkyl-, aryl- 
or alicyclic-substituted pyrazines in this group of flavouring substances. Almost all data available 
come from one paper (Hawksworth and Scheline, 1975) and a few review papers (Beedham, 1985; 
Beedham, 1988; Parkinson, 1996a). Additional information provided in other papers is supportive of 
the metabolic conversions that have been described, but of little quantitative relevance as they concern 
substances that are widely different from the candidate substances in this group and the supporting 
ones evaluated by the JECFA.  
Pyrazines with a simple alkyl substituent (e.g. [FL-no: 14.097]) may be expected to be oxidised at the 
side chain to give the corresponding carboxylic acid. If such oxidations are not possible, e.g. due to 
steric hindrance, hydroxylation of the pyrazine ring may occur [FL-no: 14.091, 14.101, 14.111, 14.129 
and 14.170]. The bicyclic pyrazine derivatives with an additional alicyclic or aryl ring substituent [FL-
no: 14.099, 14.102, 14.108, 14.113, 14.139, 14.147, 14.148 and 14.161] may be better substrates for 
ring hydroxylation, which seems to be carried out preferably by molybdenum hydroxylases. The 
candidate substances bearing a ketone ring substituent [FL-no: 14.081, 14.083, 14.084, 14.086 and 
14.087] may be reduced at the carbonyl in the side chain to give the corresponding alcohol. The five 
monocyclic pyrazine derivatives with a methoxy side chain [FL-no: 14.051, 14.057, 14.112, 14.126 
and 14.127] may be expected to be metabolised via both ring hydroxylation and O-demethylation of 
the methoxy side chain. Accordingly, the monocyclic pyrazine derivatives with an ethoxy side chain 
[FL-no: 14.109] may also be expected to be metabolised via both ring hydroxylation and O-
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deethylation of the ethoxy side chain. With the resulting products of any of these flavouring 
substances, conjugation with glycine, sulphate or glucuronide may occur. In none of the studies, N-
oxidation or N-methylation, which would lead to the formation of bioactive metabolites, has been 
observed. This is in agreement with the reactive properties of the heterocyclic nitrogen in pyrazine 
moieties. 
Two candidate substances in this group, 2-isopropyl-3-methylthiopyrazine [FL-no: 14.122] and 2-
methyl-3-methylthiopyrazine [FL-no: 14.128], are thioethers, which may be detoxified by formation 
of a sulphoxide and subsequently a sulphone, which are both stable and usually rapidly excreted. 
Alternatively, they may also be bioactivated via S-demethylation, resulting in the formation of a 
reactive free thiol. No data were provided to show that either route predominates. For that reason, it 
cannot be anticipated that these sulphur-containing pyrazine derivatives are metabolised to innocuous 
products. Neither can it be assumed that quinoxaline [FL-no: 14.147] and its derivative 2-
methylquinoxaline [FL-no: 14.139] are metabolised to innocuous products. One of the candidate 
substances, isopropenylpyrazine [FL-no: 14.052] has a terminal double-bond (in conjugation with a 
heterocyclic aromatic ring) and it may be anticipated to be epoxidised, thereby giving rise to reactive 
metabolites (as for alkenes with terminal double bonds). It can therefore not be concluded that 
isopropenylpyrazine can be metabolised to innocuous products. 
Based on the available data, the following substances in this group [FL-no: 14.051, 14.057, 14.081, 
14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 14.099, 14.101, 14.102, 14.108, 14.109, 14.111, 
14.112, 14.113, 14.126, 14.127, 14.129, 14.148, 14.161 and 14.170] may be expected to be 
metabolised to innocuous products. Three substances [FL-no: 14.122, 14.128 and 14.052] cannot be 
anticipated to be metabolised to innocuous products. For the remaining two quinoxalines [FL-no: 
14.139 and 14.147] a concern for genotoxicity has been identified (see also Section 8.4).  
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances  
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
In previous versions of the present FGE, it was found that two of the candidate substances, 
quinoxaline [FL-no: 14.147] and 2-methylquinoxaline [FL-no: 14.139] showed possible genotoxic 
potential in vitro. Therefore, the Panel decided that the Procedure could not be applied to these two 
candidate substances nor to the structurally related 2,3-dimethylquinoxaline [FL-no: 14.108] until 
adequate genotoxicity data become available.  
Additional genotoxicity data have been submitted by the Industry (Flavour Industry, 2009a) for the 
structurally related 5-methylquinoxaline [FL-no: 14.028] and these genotoxicity data have been 
evaluated in FGE.17Rev2. The available data indicate that there is no apparent structure-activity 
relationship for the genotoxicity of quinoxalines (Hashimoto et al., 1979); thus, these compounds are 
to be considered individually.  
2,3-Dimethylquinoxaline [FL-no: 14.108] is not genotoxic in vitro and can be evaluated through the 
Procedure; conversely, in vitro data indicate a genotoxic potential for quinoxaline [FL-no: 14.147] and 
2-methylquinoxaline [FL-no: 14.139], for which no in vivo data are available. Therefore, for these two 
substances the Procedure cannot be applied until adequate genotoxicity data become available. 
For one candidate substance, 2- ,5- or 6-methoxy-3-ethylpyrazine [FL-no: 14.051] no European 
production figures were available and consequently no European exposure estimates could be 
calculated. Accordingly, the safety in use could not be assessed using the Procedure for this substance. 
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The safety evaluation of the remaining 25 candidate substances to be evaluated using the Procedure, as 
outlined in Annex I, was applied, based on the MSDI approach. The stepwise evaluations of the 
substances are summarised in Table 2. 
Step 1 
According to the decision tree approach, presented by Cramer et al., 19 candidate substances for which 
the Procedure could be applied are classified into structural class II. The six remaining substances, for 
which the Procedure could be applied, are classified into structural class III (Cramer et al., 1978). 
Step 2 
Three candidate substances cannot be anticipated to be metabolised to innocuous products: two 
sulphur-containing flavouring substances [FL-no: 14.122 and 14.128], which may be converted to a 
reactive free thiol and one substance with a terminal double bond [FL-no: 14.052] (in conjugation with 
a heterocyclic aromatic ring), which may be epoxidised giving rise to reactive metabolites.  
Therefore these three substances are evaluated along the B-side of the Procedure. 
Based on the available data, 22 substances [FL-no:  14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 
14.091, 14.097, 14.099, 14.101, 14.102, 14.108, 14.109, 14.111, 14.112, 14.113, 14.126, 14.127, 
14.129, 14.148 14.161 and 14.170] may be expected to be metabolised to innocuous products. 
Therefore, these 22 flavouring substances are evaluated along the A-side of the Procedure (Annex I). 
Step A3 
Eighteen candidate substances evaluated along the A-side of the Procedure scheme are classified into 
structural class II and four into structural class III. The estimated daily per capita intakes from use as 
flavouring substances range from 0.0024 to 12 microgram. These intakes are below the threshold of 
concern of 540 and 90 microgram/person/day for structural class II and III substances, respectively. 
Based on the results of the safety evaluation sequence of the Procedure, these 22 candidate substances 
proceeding via the A-side of the Procedure scheme do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
Step B3 
The level of intake of the candidate substance isopropenylpyrazine [FL-no: 14.052] was estimated to 
be 0.012 microgram/capita/day, which is below the threshold of concern of 540 microgram/person/day 
for structural class II substances.  
The levels of intake of the candidate substances, 2-isopropyl-3-methyl thiopyrazine [FL-no: 14.122] 
and 2-methyl-3-methylthiopyrazine [FL-no: 14.128] were estimated to be 0.061 and 0.68 
microgram/capita/day, respectively, which is below the threshold of concern of 90 
microgram/person/day for structural class III substances.  
Accordingly, these candidate substances proceed to step B4 of the Procedure. 
Step B4 
No valid toxicity study from which a NOAEL could be established was available for 
isopropenylpyrazine [FL-no: 14.052] or for any relevant supporting substance. Therefore, the Panel 
concluded that additional toxicity data are needed for this substance. 
Ninety days oral feeding studies in rats are available for two supporting substances [FL-no: 14.031 
and 14.034] structurally related to the candidate substances 2-isopropyl-3-methylthiopyrazine [FL-no: 
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14.122] and 2-methyl-3-methylthiopyrazine [FL-no: 14.128]. Although the studies are not performed 
in accordance with modern guidelines (see Section 8.2), the studies have been considered adequate for 
deriving a No Observed Adverse Effect Level (NOAEL) for each, which are 16.3 and 1.63 mg/kg 
body weight (bw) for [FL-no: 14.031 and 14.034], respectively. The combined daily per capita intake 
of 0.74 microgram for the two candidate substances [FL-no: 14.122 and 14.128] corresponds to 0.012 
microgram/kg bw/day at a body weight of 60 kg. Thus, a margin of safety of 1.4 x 105 using the 
NOAEL of 1.63 can be calculated. 2-Isopropyl-3-methylthiopyrazine [FL-no: 14.122] and 2-methyl-3-
methylthiopyrazine [FL-no: 14.128] are accordingly not expected to be of safety concern at their 
estimated levels of intake. 
Based on results of the safety evaluation sequence, 24 of the 25 candidate substances, for which the 
Procedure could be applied, are not expected to be of safety concern when used as flavouring 
substances at the estimated levels of intake, based on the MSDI approach. For the candidate substance 
isopropenylpyrazine [FL-no: 14.052], additional toxicity data is needed. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
For the candidate substances [FL-no: 14.051, 14.057, 14.109, 14.111, 14.112, 14.126 and 14.128] no 
use levels were provided. Use levels for these seven substances are required. 
Based on the mTAMDI approach, the estimated intakes for the 16 of the 17 candidate substances in 
structural class II range from 190 to 400 microgram/person/day, which is below the threshold of 
concern of 540 microgram/person/day for structural class II substances. For one substance [FL-no: 
14.170] the mTAMDI is 1100 microgram/person/day, which is above the threshold.  
The estimated intakes of the four substances [FL-no: 14.108, 14.122, 14.139 and 14.147] assigned to 
structural class III, based on the mTAMDI, range from 190 to 270 microgram/person/day, which are 
all above the threshold of concern for structural class III of 90 microgram/person/day.  
For the candidate substances [FL-no: 14.108, 14.122 and 14.170] further information is needed. This 
would include more reliable intake data and then, if required, additional toxicological data.  
For the candidate substances [FL-no: 14.139 and 14.147], additional genotoxicity data are required 
before they can be evaluated using the Procedure, based on the MSDI approach. Subsequently, more 
reliable intake data (mTAMDI) may be required. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 6.1. 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
14.057 2-Isopropyl-3-methoxypyrazine 0.085  Class II 540 
14.081 5-Acetyl-2,3-dimethylpyrazine 0.012 270 Class II 540 
14.083 2-Acetyl-5-ethylpyrazine 0.012 270 Class II 540 
14.084 2-Acetyl-5-methylpyrazine 0.0024 270 Class II 540 
14.086 2-Acetyl-6-ethylpyrazine 0.0061 270 Class II 540 
14.087 2-Acetyl-6-methylpyrazine 0.028 270 Class II 540 
14.091 2-Butyl-3-methylpyrazine 0.12 270 Class II 540 
14.097 2,5-Diethylpyrazine 0.024 270 Class II 540 
14.099 6,7-Dihydro-5,7-dimethyl-5H-
cyclopentapyrazine 
0.032 190 Class II 540 
14.101 2,5-Dimethyl-3-isopropylpyrazine 0.018 190 Class II 540 
14.102 5,6-Dimethyldihydrocyclopentapyrazine 0.1 270 Class II 540 
14.111 3-Ethyl-2,5-dimethylpyrazine 2.1  Class II 540 
14.113 5-Ethyl-6,7-dihydro-5H-cyclopentapyrazine 0.012 270 Class II 540 
14.127 2-Methoxy-3-propylpyrazine 0.061 270 Class II 540 
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14.129 2-Methyl-3-propylpyrazine 0.011 400 Class II 540 
14.148 5,6,7,8-Tetrahydro-5-methylquinoxaline 0.0073 270 Class II 540 
14.161 6,7-Dihydro-2,5-dimethyl-5H-
cyclopentapyrazine 
0.011 400 Class II 540 
14.170 5-Ethyl-2,3-dimethyl pyrazine 0.12 1100 Class II 540 
14.052 Isopropenylpyrazine 0.012 400 Class II 540 
14.051 2,5 or 6-Methoxy-3-ethylpyrazine   Class II 540 
14.108 2,3-Dimethylquinoxaline 0.049 190 Class III 90 
14.109 2-Ethoxy-3-methylpyrazine 0.012  Class III 90 
14.112 2-Ethyl-3-methoxypyrazine 0.17  Class III 90 
14.126 2-Methoxy-3-methylpyrazine 12  Class III 90 
14.122 2-Isopropyl-3-methylthiopyrazine 0.061 270 Class III 90 
14.128 2-Methyl-3-methylthiopyrazine 0.68  Class III 90 
14.139 2-Methylquinoxaline 0.12 270 Class III 90 
14.147 Quinoxaline 0.12 270 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
As two of the candidate substances, quinoxaline [FL-no: 14.147] and 2-methylquinoxaline [FL-no: 
14.139] show possible genotoxic potential in vitro, the substances are not taken through the Procedure. 
As no intake data are available for 2,5 or 6-methoxy-3-ethylpyrazine [FL-no: 14.051] the substance is 
not taken through the Procedure. These three substances are therefore not included in the calculation 
of the combined intake of the candidate substances evaluated in FGE.17Rev3. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003r; EFFA, 2007e; 
EFFA, 2007f; Flavour Industry, 2010m; EFFA, 2011e) the combined estimated daily per capita intake 
as flavourings of the 19 candidate flavouring substances assigned to structural class II is 2.7 
microgram, and of the six substances assigned to structural class III, 13.2 microgram. These values do 
not exceed the thresholds of concern for substances belonging to structural class II and III of 540 and 
90 microgram/person/day, respectively. 
The candidate substances are structurally related to 41 supporting substances evaluated by the JECFA 
at its 57th meeting (JECFA, 2002b). Based on reported production volumes, European per capita 
intakes (MSDI) could be estimated for the 41 supporting substances.  
The total combined intake of the 19 candidate substances and 32 supporting substances from structural 
class II is approximately 310 microgram/capita/day, which is below the threshold of concern for a 
compound belonging to structural class II of 540 microgram/person/day. The total combined intake of 
the six candidate substances from structural class III, and nine supporting substances from structural 
class III is approximately 50 microgram/capita/day, which is also below the threshold of concern for a 
compound belonging to structural class III of 90 microgram/person/day.  
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8. Toxicity 
8.1. Acute Toxicity 
Acute oral LD50 values are available on 18 of the 41 supporting substances. The acute oral LD50 in rats 
and mice range from 200 to more than 4000 mg/kg bw indicating a low level of oral toxicity in these 
species.  
The acute toxicity data are summarised in Annex IV, Table IV.1 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
No data are available on subacute or subchronic toxicity for the candidate substances. Data on 
subchronic toxicity are available on 17 of the 41 supporting substances. Most of the studies were 
performed at single dose levels and all studies were performed in rats. The No Observed Adverse 
Effect Level (NOAEL) of the substances were in the range from 0.44 mg/kg bw to 55 mg/kg body 
weight (bw). 
Toxicity studies on three supporting substances used for deriving the NOAELs used in the Procedure 
are briefly reported in the following. 
Pyrazinyl methyl sulphide [FL-no: 14.034] and pyrazinylethanethiol [FL-no: 14.031] 
The supporting substances pyrazinyl methyl sulphide [FL-no: 14.034] and pyrazinylethanethiol [FL-
no: 14.031] were administered in the feed to male and female rats (16 animals/sex) for 13 weeks at 
doses of 1.63 mg/kg bw/day and 16.30 mg/kg bw/day, respectively. After 90 days, all animals were 
killed, subjected to detailed necropsy examinations, and liver and kidney weights were measured. A 
wide range of tissues and organs from each animal were preserved and histopathological examinations 
were performed on major organs and tissues. The authors stated that no major differences were 
observed between groups of treated and control animals, based on measurements of growth, food 
intake, haematological parameters, blood urea determinations, organ weights and gross and 
histopathologic examinations. However, no numeric data were reported. The only levels tested (1.63 
and 16.30 mg/kg bw/day) have been taken as NOAELs for pyrazinyl methyl sulphide [FL-no: 14.034] 
and pyrazinylethanethiol [FL-no: 14.031], respectively (Posternak et al., 1975). 
5-Methylquinoxaline [FL-no: 14.028] 
The supporting substance 5-methylquinoxaline [FL-no: 14.028] was administered in the feed to male 
and female rats (16 animals/sex) for 90 days at a single dose of 17.1 mg/kg bw/day. After 7 weeks and 
after 13 weeks, 50 % of the animals were killed, and liver and kidney weights were measured and 
gross and histological examinations were carried out on a wide range of organs. The authors stated 
that no major differences were observed between groups of treated and control animals, based on 
measurements of growth, food intake, haematological parameters, blood urea determinations, organ 
weights and gross and histopathologic examinations. However, no numeric data were reported. The 
only level tested (17.1 mg/kg bw/day) has been taken as NOAEL for 5-methylquinoxaline [FL-no: 
14.028] (Posternak et al., 1969) 
No studies are available on chronic toxicity or on carcinogenicity for either candidate or supporting 
substances. 
The repeated dose toxicity are summarised in Annex IV, Table IV.2. 
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8.3. Developmental / Reproductive Toxicity Studies 
Data are available for four of the supporting substances 2,3-dimethylpyrazine, 2,5-dimethylpyrazine, 
2,6-dimethylpyrazine, 2,3,5,6-tetramethylpyrazine. 2,5-Dimethylpyrazine [FL-no: 14.020] has been 
reported to occur naturally in the urine of female mice at concentrations of 0.25 μg/l. A study of a 
mixture of 2,5-dimethylpyrazine with five naturally occurring ketones and esters was reported to delay 
puberty in juvenile female mice, but the compound responsible for this effect was not identified 
(Novotny et al., 1986). The effect of isomers of dimethylpyrazine on reproductive organs in male and 
female rats has been studied. (Yamada et al., 1992; Yamada et al., 1993; Yamada et al., 1994). The 
effects on reproductive organ parameters have been described after subcutaneous (s.c.) injection of 
2,5-dimethylpyrazine [FL-no: 14.020] at doses > 30 mg/kg bw, which can be considered as the 
NOAEL. Also 2,6-methylpyrazine [FL-no: 14.021]) showed some effects, but to a lesser extent while, 
2,3- dimethylpyrazine [FL-no: 14.050] showed no effect. However, the relevance of s.c. route of 
administration is limited, considering the use of the chemical as a flavouring substance. In addition, as 
recently reviewed, neither the mechanism(s) nor the relevance for the human reproductive system have 
been clarified (Koyama, 2004). In any case, the NOAEL of 30 mg/kg bw is orders of magnitude 
higher than the predicted level of exposure as a flavouring substance, according to the MSDI 
approach. A study on a fourth supporting substance, 2,3,5,6-tetramethylpyrazine [FL-no: 14.018], 
showed no adverse effects on several reproductive parameters after oral administration (Vollmuth et 
al., 1997) 
Developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Genotoxicity data were provided for three of the candidate substances and for 11 of the supporting 
substances. The three candidate substances are quinoxaline [FL-no: 14.147] and its derivatives 2-
methylquinoxaline [FL-no: 14.139] and 2,3-dimethylquinoxaline [FL-no: 14.108].  
Genotoxicity data on Candidate substances 
In in vitro studies, quinoxaline [FL-no: 14.147], up to 10000 microgram/plate, and 2,3-
dimethylquinoxaline [FL-no: 14.108], up to 2500 microgram/plate, with and without metabolic 
activation, did not cause reverse mutation in various strains of Salmonella typhimurium (Table IV.4). 
Two studies on 2-methylquinoxaline [FL-no: 14.139] are available, one study with a positive, the 
other with negative result in the Ames test. However, quinoxaline [FL-no: 14.147] at 250 
microgram/ml culture medium and with metabolic activation was found to induce TFT-mutants in the 
mouse lymphoma mutagenesis assay (L5178Y TK+/- cells). This study was conducted in accordance 
with the OECD guideline 476 and therefore considered valid. 
No adequate in vivo studies on genotoxicity of the candidate substances are available. A study of the 
potential of quinoxaline [FL-no: 14.147] to induce sperm head abnormalities (Topham, 1980) did not 
address a genetic endpoint and the Panel considered it could not be used for evaluation of genotoxicity 
of this substance. 
Genotoxicity data on Supporting substances  
Substituted pyrazines 
In vitro, 2-methylpyrazine [FL-no: 14.027], ethylpyrazine [FL-no: 14.022], 2,3-dimethylpyrazine [FL-
no: 14.050], 2,5-dimethylpyrazine [FL-no: 14.020], 2,6-dimethylpyrazine [FL-no: 14.021], 2,3-
diethylpyrazine [FL-no: 14.005], 2,3,5-trimethylpyrazine [FL-no: 14.019], pyrazine [FL-no: 14.144] 
and (2, 5 or 6)-methoxy-3-methylpyrazine [FL-no: 14.025] were tested for their ability to cause 
reverse mutation in various strains of S. typhimurium and consistently revealed negative results with 
and without metabolic activation (Table IV.4).  
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In one of these studies, 2-methylpyrazine, ethylpyrazine, 2,5-dimethylpyrazine, 2,6-dimethylpyrazine, 
and pyrazine were also tested for their potential to cause genotoxicity in Saccharomyces cerevisiae 
and chromosomal aberrations in Chinese hamster ovary cells (Table IV.4) (Stich et al., 1980). This 
study has strong limitations for the following reasons. The positive results were observed only in a 
narrow range of exceedingly high and toxic concentrations. In the case of chromosome aberrations, the 
concentration used exceeded the maximum level (5 mg/ml) recommended by OECD. It has been 
shown (Galloway, 2000) that in vitro chromosome breaking can occur secondary to toxicity and/or 
changed physiological conditions (e.g., pH, osmolarity) with compounds not able to react with DNA 
and negative in the Ames test and in vivo. The S. cerevisiae D5 assay for induction of "aberrant 
colonies" is not routinely used and has not been validated at international level due to the uncertainty 
on the various effects involved. Thus, the positive results reported by Stich et al. (Stich et al., 1980) 
are considered of limited value and not relevant for hazard and risk assessment. Furthermore, pyrazine 
was found negative in a wide range of concentrations both in the Salmonella assay and in the mouse 
lymphoma TK assay (Fung et al., 1988). 
Quinoxalines 
5-Methylquinoxaline [FL-no: 14.028] was examined for its mutagenic potential in Salmonella 
typhimurium strains TA98, TA100, TA1535 and TA1537, as well as in Escherichia coli strain WP2 
uvrA. The study was conducted according to GLP and was in compliance with OECD Guideline 471. 
No evidence of mutagenicity was found with or without S9 metabolic activation at concentrations up 
to 5,000 µg/plate (Ogura and Wakamatsu, 2004).  
5-Methylquinoxaline was examined for its potential to induce structural chromosome aberrations in 
mammalian cells. The study was conducted according to GLP and was in compliance with OECD 
Guideline 473. The test system used was a subculture of Chinese hamster lung-derived CHL/IU cells 
that were exposed to the test material at concentrations of 320, 480 and 720 µg/mL without S9 mix, 
and 72.0, 228 and 720 µg/mL with S9 mix. The percentage of “cell productivity” (the cell number was 
measured and expressed as relative growth rate compared to negative control) was reported as a 
parameter for cytotoxicity. The Panel considered that 5-methylquinoxaline was found to induce 
chromosomal aberrations in cultured mammalian cells in the presence of metabolic activation. 
Additionally, an increased frequency of polyploid cells up to 12.5 % of the middle dose compared to 0 
% in the control was observed in the presence and absence of metabolic activation at concentrations 
which induced only low cytotoxicity (Ajimu and Kawaguchi, 2004a).  
In vivo data are available for two structurally related substances only, (2, 5 or 6)-methoxy-3-
methylpyrazine [FL-no: 14.025 (mixture of three structural isomers)] and 5-methylquinoxaline [FL-
no: 14.028].  
5-Methylquinoxaline [FL-no: 14.028] was examined for its potential to induce micronucleated 
polychromatic erythrocytes (MNPCEs) in the bone marrow. The test material was administered daily 
(gavage) for two consecutive days to seven week old and six week old male SPF ICR (Crj:CD-1) mice 
at dosages of 125, 250 and 500 mg/kg/day (6 animals/dose). Microscopic examination of femoral bone 
marrow cells was conducted randomly from 5 animals. Two thousand polychromatic erythrocytes 
(PCE) per animal were analyzed microscopically (x1000), and the number of micronucleated 
polychromatic erythrocytes (MNCPE) was recorded. In order to evaluate the PCE/NCE ratio, the 
number of PCEs out of 200 total erythrocytes (PCEs plus NCEs) was recorded. The test was 
considered positive if the MNPCE frequencies in one or more treatment groups were significantly 
higher than that in the negative control groups. No significant increase of micronucleated 
polychromatic erythrocyte frequency was observed in these treatment groups compared with the 
negative control group. The PCE/NCE ratio was not changed (Ajimu and Kawaguchi, 2004b). Based 
on the PCE/NCE ratio there is no indication that the substance reached the bone marrow, however, the 
Panel noted that the high dose was the maximum tolerated dose since clinical signs of toxicity have 
been observed after oral intake. Additionally, a doubling of this dose was lethal for two out of six 
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animals in a preliminary test. Thus, the Panel considered it reasonable to assume that the substance 
was systemically available and reached the bone marrow. 
For (2, 5 or 6)-methoxy-3-methylpyrazine [FL-no: 14.025], a test for Basc mutation was performed in 
Drosophila with a concentration of 10 mmol/L (140 microgram/ml) in the solutions/emulsions fed to 
the flies, with no mutagenic effect (Table IV.5). Secondly, male and female NMRI mice were treated 
once orally with 87, 174 or 248 mg/kg bw, bone-marrow smears were prepared only at one sampling 
time (at 30 hours) after treatment. There was no increase in the frequency of micronuclei in 
polychromatic erythrocytes (Table IV.5). The PCE/NCE ratio was not reported and thus, it is not clear 
if the test substance reached the bone marrow. However from this study, there is no evidence of 
genotoxic potential. 
Conclusion on Genotoxicity 
The available data indicate that apparently there is no simple structure-activity relationship for the 
genotoxicity of quinoxalines, because the profile of genotoxic events in vitro differs for the various 
congeners (point mutations for [FL no: 14.139] and [FL-no: 14.147] vs chromosomal aberrations for 
the supporting substance [FL no: 14.028]). Therefore these compounds are to be evaluated based on 
substance-specific data for each individual quinoxaline derivative. 
In vitro data indicate a genotoxic potential for quinoxaline [FL-no: 14.147] and 2-methylquinoxaline 
[FL-no: 14.139], for which no in vivo data are available. Therefore, for these two substances the 
Procedure cannot be applied until adequate genotoxicity data become available. Conversely, for the 
supporting substance 5-methylquinoxaline [FL-no: 14.028] a negative Micronucleus assay is available.  
The candidate substance 2,3-dimethylquinoxaline [FL-no: 14.108] is not considered genotoxic in vitro 
and hence can be evaluated through the Procedure (three negative bacterial reverse gene mutation 
assays which, although limited, consistently indicate lack of genotoxicity). 
The Panel concluded that no genotoxic potential is indicated for 26 candidate substances, including 
2,3-dimethylquinoxaline [FL-no: 14.108]. For these substances, the available data do not preclude 
their evaluation through the Procedure. 
Genotoxicity data are summarised in Annex IV, Table IV.4 and IV.5. 
9. Conclusions 
This group of flavouring substances consists of 28 candidate substances, all of which contain a 
pyrazine moiety. In 20 substances [FL-no: 14.051, 14.052, 14.057, 14.081, 14.083, 14.084, 14.086, 
14.087, 14.091, 14.097, 14.101, 14.109, 14.111, 14.112, 14.122, 14.126, 14.127, 14.128, 14.129 and 
14.170] only one heterocyclic ring is present. In five candidate substances a pyrazine ring is fused 
with either cyclopentane [FL-no: 14.099, 14.102, 14.113 and 14.161] or with cyclohexane [FL-no: 
14.148]. All of these 25 substances have different ring substituents. In 16 of them, the substituents are 
simple alkyl chains and/or ketones. In nine, the substituents are, next to alkyl chains, either a methoxy- 
([FL-no: 14.051 14.057, 14.112, 14.126 and 14.127], an ethoxy- [FL-no: 14.109], a thiomethyl- [FL-
no: 14.122 and 14.128]) or an isopropenyl residue [FL-no: 14.052]. In the remaining three candidate 
substances the pyrazine ring is fused with benzene giving quinoxalines. In two of the quinoxalines 
[FL-no 14.139 and 14.108] the pyrazine ring also bears one or two methyl substituents; in the third no 
substituents are present (quinoxaline [FL-no: 14.147]). 
For the five flavouring substances, which possess one or two chiral centres [FL-no: 14.099, 14.102, 
14.113, 14.148 and 14.161], the stereoisomeric composition has been specified.  
Twenty candidate substances are classified into structural class II and eight are classified into 
structural class III. 
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Twenty-four flavouring substances in the present group have been reported to occur naturally in a 
wide range of food items. 
According to the default MSDI approach, the flavouring substances in this group, which are evaluated 
through the Procedure and for which Industry has provided intake data, have intakes in Europe from 
0.0024 to 12 microgram/capita/day. These values are below the threshold of concern value for both 
structural class II (540 microgram/person/day) and structural class III (90 microgram/person/day) 
substances. For one candidate substance [FL-no: 14.051] no intake data are available preventing it 
from being evaluated through the Procedure. 
The available data indicate that apparently there is no simple structure-activity relationship for the 
genotoxicity of quinoxalines, of which three are evaluated in this FGE, because the profile of 
genotoxic events in vitro differs for the various congeners (point mutations for [FL no: 14.139] and 
[FL-no: 14.147] vs chromosomal aberrations for the supporting substance [FL no: 14.028]). Therefore 
these compounds are to be evaluated based on substance-specific data for each individual quinoxaline 
derivative. 
In vitro data indicate a genotoxic potential for quinoxaline [FL-no: 14.147] and 2-methylquinoxaline 
[FL-no: 14.139], for which no in vivo data are available. Therefore, for these two substances the 
Procedure cannot be applied until adequate genotoxicity data become available. Conversely, for the 
supporting substance 5-methylquinoxaline [FL-no: 14.028] a negative Micronucleus assay is available.  
The candidate substance 2,3-dimethylquinoxaline [FL-no: 14.108] is not considered genotoxic in vitro 
and hence can be evaluated through the Procedure. No genotoxic potential at gene or chromosome 
level is indicated for the remaining alkyl- and cycloalkyl-substituted pyrazines. Therefore these 
substances may also be evaluated through the Procedure. 
So, in total, 25 substances are evaluated through the Procedure, based on the MSDI approach 
Appendix I). 
Twenty-two of the alkyl- and cycloalkyl-substituted pyrazines and one of the alkyl-substituted 
quinoxalines may be expected to be metabolised to innocuous products [FL-no: 14.051, 14.057, 
14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 14.099, 14.101, 14.102, 14.108, 14.109, 
14.111, 14.112, 14.113, 14.126, 14.127, 14.129, 14.148, 14.161 and 14.170]. Regarding the remaining 
five substances, they cannot be anticipated to be metabolised to innocuous products. Two sulphur-
containing flavouring substances [FL-no: 14.122 and 14.128], may be converted to a reactive free 
thiol. Neither can it be assumed that quinoxaline [FL-no: 14.147] and its derivative [FL-no: 14.139] 
are metabolised to innocuous products. One substance with a terminal double bond [FL-no: 14.052] 
(in conjugation with a heterocyclic aromatic ring), may be epoxidised giving rise to reactive 
metabolites. 
Where toxicity data were available for substances evaluated using the Procedure, they were consistent 
with the conclusions in the present FGE. 
It is considered that on the basis of the default MSDI approach, the 24 of the 25 candidate substances 
evaluated through the Procedure would not give rise to safety concerns at the estimated levels of 
intake arising from their use as flavouring substances. No valid toxicity study from which a NOAEL 
could be established was available for isopropenylpyrazine [FL-no: 14.052] or for any relevant 
supporting substance. Therefore, the Panel concluded that additional toxicity data are needed for this 
substance. 
When the estimated intakes, of the substances evaluated through the Procedure, were based on the 
mTAMDI approach they ranged from 190 to 1100 microgram/person/day for the flavouring 
substances from structural class II for which data have been provided. The intakes for 16 substances 
were below the threshold of concern for structural class II of 540 microgram/person/day. These 16 
substances are also expected to be metabolised to innocuous products. For one substance [FL-no: 
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14.170] the mTAMDI is above the threshold. The estimated intakes (mTAMDI) of the two flavouring 
substances [FL-no: 14.108 and 14.122 ] assigned to structural class III, for which use levels have been 
submitted and which were evaluated through the Procedure, are 190 and 270 microgram/person/day, 
respectively, which are above the threshold of concern for structural class III of 90 
microgram/person/day. Thus, for three flavouring substances [FL-no: 14.108, 14.122 and 14.170] the 
intakes estimated on the basis of the mTAMDI, exceed the relevant threshold for their structural class, 
to which the flavouring substance has been assigned. For seven substances [FL-no: 14.051, 14.057, 
14.109, 14.111, 14.112, 14.126 and 14.128], no use levels were provided. Therefore, for these 10 
substances more reliable exposure data (mTAMDI) are required. On the basis of such additional data, 
the flavouring substances should be re-evaluated using the Procedure. Subsequently, additional 
toxicity data might become necessary. 
Thus, in conclusion, only 25 of the 28 candidate substances were evaluated through the Procedure, 
based on the MSDI approach, as two flavouring substances, quinoxaline [FL-no: 14.147] and 2-
methylquinoxaline [FL-no: 14.139] could not be evaluated through the Procedure until adequate 
genotoxicity data become available and one substance, 2- ,5- or 6-methoxy-3-ethylpyrazine [FL-no: 
14.051], was presented with no intake data and therefore cannot not be evaluated through the 
Procedure.  
In order to determine whether the conclusion for the 25 candidate substances which have been 
evaluated using the Procedure (MSDI approach) can be applied to the materials of commerce, it is 
necessary to consider the available specifications. Adequate specifications including complete purity 
criteria and identity for the materials of commerce have been provided for 24 flavouring substances 
evaluated through the Procedure. For one substance [FL-no: 14.102], the composition of mixture has 
not been specified sufficiently. So, the final evaluation of the materials of commerce cannot be 
performed for one substance, 5,6-dimethyldihydrocyclopentapyrazine [FL-no: 14.102], pending 
further information on composition of mixture.  
For one substance [FL-no: 14.052] evaluated through the Procedure, additional toxicity data are 
required.  
For the remaining 23 substances [FL-no: 14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 
14.097, 14.099, 14.101, 14.108, 14.109, 14.111, 14.112, 14.113, 14.122, 14.126, 14.127, 14.128, 
14.129, 14.148 14.161 and 14.170], the Panel concluded that they would present no safety concern at 
the level of intake estimated on the basis of the MSDI approach.  
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN FGE.17REV3 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 17, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
14.051 
 
2,5 or 6-Methoxy-3-ethylpyrazine N
N
O
 
3280 
11329 
68739-00-4 
 
 
124.14 
 
 
 
 
 
 
 
 
AV 6), BP 7), ID 8), MP 9), 
PF 10), RI 11), SG 12), SE 
13), SW 14) 
Registername to be changed 
to mixture of 2-, 5- or 6- 
methoxy-3-ethylpyrazine. 
14.052 
 
Isopropenylpyrazine 
N
N
3296 
11341 
38713-41-6 
Liquid 
C7H8N2 
120.16 
Practically insoluble 
or insoluble 
Soluble 
73-75 (23 hPa) 
 
NMR 
99 % 
1.480-1.486 
0.964-0.968 
 
 
14.057 
 
2-Isopropyl-3-methoxypyrazine 
N
N O
3358 
11344 
25773-40-4 
Liquid 
C8H12N2O 
152.20 
Soluble 
Soluble 
120-125 (26 hPa 
 
MS 
97 % 
1.492-1.499 
1.010-1.022 
 
 
14.081 
 
5-Acetyl-2,3-dimethylpyrazine 
N
N
O  
 
54300-10-6 
Solid 
C8H10N2O 
150.18 
Soluble 
Freely soluble 
308 
151 
MS 
95 % 
n.a. 
n.a. 
 
 
14.083 
 
2-Acetyl-5-ethylpyrazine 
N
N
O  
 
43108-58-3 
Solid 
C8H10N2O 
150.18 
Soluble 
Freely soluble 
303 
138 
NMR 
95 % 
n.a. 
n.a. 
 
 
14.084 
 
2-Acetyl-5-methylpyrazine 
N
N
O  
11297 
22047-27-4 
Solid 
C7H8N2O 
136.15 
Soluble 
Freely soluble 
80 (11 hPa) 
56 
MS 
95 % 
n.a. 
n.a. 
 
 
14.086 
 
2-Acetyl-6-ethylpyrazine 
N
N
O  
11295 
34413-34-8 
Solid 
C8H10N2O 
150.18 
Soluble 
Freely soluble 
302 
137 
NMR 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 17, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
14.087 
 
2-Acetyl-6-methylpyrazine 
N
N
O  
11298 
22047-26-3 
Solid 
C7H8N2O 
136.15 
Soluble 
Freely soluble 
280 
33 
MS 
95 % 
n.a. 
n.a. 
 
 
14.091 
 
2-Butyl-3-methylpyrazine 
N
N
 
 
 
15987-00-5 
Solid 
C9H14N2 
150.22 
Slightly soluble 
Freely soluble 
84 (12 hPa) 
100 
MS 
95 % 
n.a. 
n.a. 
 
 
14.097 
 
2,5-Diethylpyrazine 
N
N
 
 
11306 
13238-84-1 
Solid 
C8H12N2 
136.20 
Slightly soluble 
Freely soluble 
187 
88 
MS 
95 % 
n.a. 
n.a. 
 
 
14.099 
 
6,7-Dihydro-5,7-dimethyl-5H-
cyclopentapyrazine 
N
N
 
 
41330-21-6 
Solid 
C9H12N2 
148.21 
Slightly soluble 
Freely soluble 
84 (13 hPa) 
113 
MS 
95 % 
n.a. 
n.a. 
 
Meso-form (RS- = SR–
form) equal 50 % and RR- 
and SS-forms 25 % each 
(EFFA, 2011a). 
14.101 
 
2,5-Dimethyl-3-isopropylpyrazine 
N
N  
11318 
40790-20-3 
Solid 
C9H14N2 
150.22 
Slightly soluble 
Freely soluble 
276 
97 
NMR 
95 % 
n.a. 
n.a. 
 
 
14.102 
 
5,6-
Dimethyldihydrocyclopentapyrazin
e 
N
N
N
N
 
 
 
38917-61-2 
Liquid 
C9H12N2 
148.21 
Slightly soluble 
Freely soluble 
230-231 
 
MS 
98 % 
1.524-1.532 
1.020-1.030 
 
Change name to: 2,5-
dimethyl-6,7-dihydro-5H-
cyclopentapyrazine. 
Racemate. Covers mix of 
2,5-dimethyl-6,7-dihydro-
5H-cyclopentapyrazine (60 -  
100 %) & 3,5-dimethyl-6,7-
dihydro-5H-
cyclopentapyrazine (30 - 60 
%) (EFFA, 2011a). 
Composition of mixture to 
be specified. 
14.108 
 
2,3-Dimethylquinoxaline 
N
N
 
 
 
2379-55-7 
Solid 
C10H10N2 
158.20 
Slightly soluble 
Freely soluble 
128 (2 hPa) 
106 
MS 
95 % 
n.a. 
n.a. 
 
 
14.109 
 
2-Ethoxy-3-methylpyrazine 
N
N
O
3569 
11325 
32737-14-7 
Liquid 
C7H10N2O 
138.17 
Soluble 
Soluble 
176 
 
MS 
97 % 
1.493-1.497 
1.034-1.041 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 17, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
14.111 
 
3-Ethyl-2,5-dimethylpyrazine N
N
3149 
2246 
13360-65-1 
Liquid 
C8H12N2 
136.19 
Soluble 
Soluble 
176 
 
MS 
97 % 
1.493-1.497 
1.034-1.041 
 
Registername to be changed 
to 2,5-Dimethyl-3-
ethylpyrazine. 
14.112 
 
2-Ethyl-3-methoxypyrazine 
N
N O 3280 
11329 
25680-58-4 
Liquid 
C7H10N2O 
132.14 
Soluble 
Soluble 
95 (1,3 hPa) 
 
MS 
99 % 
1.497-1.505 
1.036-1.052 
 
 
14.113 
 
5-Ethyl-6,7-dihydro-5H-
cyclopentapyrazine 
N
N  
 
52517-53-0 
Solid 
C9H12N2 
148.21 
Slightly soluble 
Freely soluble 
278 
117 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2007m). 
14.122 
 
2-Isopropyl-3-methylthiopyrazine 
N
N
S
 
11342 
67952-59-4 
Solid 
C8H12N2S 
168.28 
Slightly soluble 
Freely soluble 
317 
108 
MS 
95 % 
n.a. 
n.a. 
 
 
14.126 
 
2-Methoxy-3-methylpyrazine N
N
O
 
3183 
2266 
2847-30-5 
Liquid 
C6H8N2O 
124.14 
Soluble 
Soluble 
85 (1.3 hPa) 
 
MS 
97 % 
1.505-1.510 
1.060-1.090 
 
 
14.127 
 
2-Methoxy-3-propylpyrazine 
N
N O
 
 
 
25680-57-3 
Solid 
C8H12N2O 
152.20 
Slightly soluble 
Freely soluble 
271 
111 
MS 
95 % 
n.a. 
n.a. 
 
 
14.128 
 
2-Methyl-3-methylthiopyrazine 
N
N
S  
 
2882-20-4 
Liquid 
C6H8N2S 
140.21 
Soluble 
Soluble 
87 (1.3 hPa) 
 
MS 
99 % 
1.570-1.590 
1.133-1.153 
 
 
14.129 
 
2-Methyl-3-propylpyrazine 
N
N
 
 
 
15986-80-8 
Liquid 
C8H12N2 
136.20 
Practically insoluble 
or insoluble 
Freely soluble 
190 
 
MS 
95 % 
1.495-1.501 
0.978-0.984 
 
 
14.139 
 
2-Methylquinoxaline 
N
N
 
 
 
7251-61-8 
Solid 
C9H8N2 
144.18 
Slightly soluble 
Freely soluble 
245 
132 
MS 
95 % 
n.a. 
n.a. 
 
 
14.147 
 
Quinoxaline 
N
N  
11365 
91-19-0 
Solid 
C8H6N2 
130.15 
Slightly soluble 
Freely soluble 
225 
30 
MS 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 17, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
95 % 
14.148 
 
5,6,7,8-Tetrahydro-5-
methylquinoxaline 
N
N  
 
52517-54-1 
Solid 
C9H12N2 
148.21 
Slightly soluble 
Freely soluble 
72 (4 hPa) 
114 
MS 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2007m). 
14.161 
 
6,7-Dihydro-2,5-dimethyl-5H-
cyclopentapyrazine 
N
N 4702 
11310 
38917-61-2 
Solid 
C9H12N2 
148.21 
Practically insoluble 
or insoluble 
Freely soluble 
91 (16 hPa) 
110 
MS 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2007m). 
14.170 
 
5-Ethyl-2,3-dimethyl pyrazine 
N
N
 
4434 
 
15707-34-3 
Liquid 
C8H12N2 
136.19 
Slightly soluble 
Soluble 
191 
 
NMR MS 
98 % 
1.4982 
0.964 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) AV: Missing minimum assay value. 
7) BP: Missing boiling point. 
8) ID: Missing identification test. 
9) MP: Missing melting point. 
10) PF: Missing data on physical form. 
11) RI: Missing refractive index. 
12) SG: Missing specific gravity. 
13) SE: Missing data on solubility in ethanol. 
14) SW: Missing data on solubility. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
14.057 
 
2-Isopropyl-3-methoxypyrazine 
N
N O
0.085 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.081 
 
5-Acetyl-2,3-dimethylpyrazine 
N
N
O 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.083 
 
2-Acetyl-5-ethylpyrazine 
N
N
O 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.084 
 
2-Acetyl-5-methylpyrazine 
N
N
O 0.0024 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.086 
 
2-Acetyl-6-ethylpyrazine 
N
N
O 0.0061 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.087 
 
2-Acetyl-6-methylpyrazine 
N
N
O 0.028 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.091 
 
2-Butyl-3-methylpyrazine 
N
N 0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.097 
 
2,5-Diethylpyrazine 
N
N 0.024 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
14.099 
 
6,7-Dihydro-5,7-dimethyl-5H-
cyclopentapyrazine 
N
N
0.032 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.101 
 
2,5-Dimethyl-3-
isopropylpyrazine 
N
N 0.018 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.102 
 
5,6-
Dimethyldihydrocyclopentapyraz
ine 
N
N
N
N 0.1 
 
Class II 
A3: Intake below threshold 
4) 7)  
14.111 
 
3-Ethyl-2,5-dimethylpyrazine N
N
2.1 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.113 
 
5-Ethyl-6,7-dihydro-5H-
cyclopentapyrazine 
N
N 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.127 
 
2-Methoxy-3-propylpyrazine 
N
N O 0.061 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.129 
 
2-Methyl-3-propylpyrazine 
N
N 0.011 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.148 
 
5,6,7,8-Tetrahydro-5-
methylquinoxaline 
N
N 0.0073 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.161 
 
6,7-Dihydro-2,5-dimethyl-5H-
cyclopentapyrazine 
N
N 0.011 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.170 
 
5-Ethyl-2,3-dimethyl pyrazine 
N
N 0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
14.052 
 
Isopropenylpyrazine 
N
N
0.012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
14.051 
 
2,5 or 6-Methoxy-3-
ethylpyrazine 
N
N
O
 
 
Class II 
No evaluation 
  a) 
14.108 
 
2,3-Dimethylquinoxaline 
N
N 0.049 
 
Class III 
A3: Intake below threshold 
4) 6)  
14.109 
 
2-Ethoxy-3-methylpyrazine 
N
N
O
0.012 
 
Class III 
A3: Intake below threshold 
4) 6)  
14.112 
 
2-Ethyl-3-methoxypyrazine 
N
N O 0.17 
 
Class III 
A3: Intake below threshold 
4) 6)  
14.126 
 
2-Methoxy-3-methylpyrazine N
N
O 12 
 
Class III 
A3: Intake below threshold 
4) 6)  
14.122 
 
2-Isopropyl-3-
methylthiopyrazine 
N
N
S
0.061 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.128 
 
2-Methyl-3-methylthiopyrazine 
N
N
S
 
0.68 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.139 
 
2-Methylquinoxaline 
N
N 0.12 
 
Class III 
No evaluation 
  b) 
14.147 
 
Quinoxaline 
N
N 0.12 
 
Class III 
No evaluation 
  c) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
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4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) No production volume for EU available. 
b) Additional genotoxicity data required. 
c) Additional genotoxicity data required. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
14.005 2,3-Diethylpyrazine N
N  
3136 
534 
15707-24-1 
771 
JECFA specification (JECFA, 
2001c) 
1.6  
No safety concern a) 
Category B b) 
 
14.006 2-Ethyl-3-methylpyrazine N
N  
3155 
548 
15707-23-0 
768 
JECFA specification (JECFA, 
2001c). 
 
72  
No safety concern a) 
Category B b) 
 
14.015 5,6,7,8-Tetrahydroquinoxaline N
N  
3321 
721 
34413-35-9 
952 
JECFA specification (JECFA, 
2001c) 
8  
No safety concern a) 
Category B b) 
 
14.017 2-Ethyl-5-methylpyrazine N
N
3154 
728 
13360-64-0 
770 
JECFA specification (JECFA, 
2001c) 
4.0  
No safety concern a) 
Category B b) 
 
14.018 2,3,5,6-Tetramethylpyrazine 
N
N
 
3237 
734 
1124-11-4 
780 
JECFA specification (JECFA, 
2001c) 
6.7  
No safety concern a) 
Category B b) 
 
14.019 2,3,5-Trimethylpyrazine N
N  
3244 
735 
14667-55-1 
774 
JECFA specification (JECFA, 
2001c) 
100  
No safety concern a) 
Category B b) 
 
14.020 2,5-Dimethylpyrazine N
N  
3272 
2210 
123-32-0 
766 
JECFA specification (JECFA, 
2001c) 
19  
No safety concern a) 
Category B b) 
 
14.021 2,6-Dimethylpyrazine N
N  
3273 
2211 
108-50-9 
767 
JECFA specification (JECFA, 
2001c) 
1.3  
No safety concern a) 
Category B b) 
 
14.022 Ethylpyrazine 
N
N
 
3281 
2213 
13925-00-3 
762 
JECFA specification (JECFA, 
2001c) 
2.2  
No safety concern a) 
Category B b) 
 
14.024 2-Ethyl-3,5-dimethylpyrazine N
N
3150 
2245 
13925-07-0 
776 
JECFA specification (JECFA, 
2001c) 
1.2  
No safety concern a) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
14.025 2,5 or 6-Methoxy-3-
methylpyrazine 
N
N O N
N
O
N
N
O
2-Methoxy-3-methylpyrazine 6-Methoxy-3-methylpyrazine
5-Methoxy-3-methylpyrazine
3183 
2266 
63450-30-6 
788 
JECFA specification (JECFA, 
2001c) 
2.2  
No safety concern a) 
Category B b) 
 
14.026 2-Isopropyl-5-methylpyrazine 
N
N
3554 
2268 
13925-05-8 
772 
JECFA specification (JECFA, 
2001c) 
0.024  
No safety concern a) 
Category B b) 
 
14.027 2-Methylpyrazine N
N  
3309 
2270 
109-08-0 
761 
JECFA specification (JECFA, 
2001c) 
17  
No safety concern a) 
Category B b) 
 
14.028 5-Methylquinoxaline 
N
N
 
3203 
2271 
13708-12-8 
798 
JECFA specification (JECFA, 
2001c) 
22  
No safety concern a) 
Category B b) 
 
14.031 Pyrazineethanethiol 
N
N SH 3230 
2285 
35250-53-4 
795 
JECFA specification (JECFA, 
2001c) 
0.13  
No safety concern a) 
Category B b) 
 
14.032 Acetylpyrazine 
N
N
O
 
3126 
2286 
22047-25-2 
784 
JECFA specification (JECFA, 
2001c) 
12  
No safety concern a) 
Category B b) 
 
14.034 Pyrazinyl methyl sulfide 
N
N S
 
3231 
2288 
21948-70-9 
796 
JECFA specification (JECFA, 
2001c) 
0.0061  
No safety concern a) 
Category B b) 
 
14.035 2-Methyl-3,5 or 6-
methylthiopyrazine 
N
N
N
N
N
N
S S
S
3-Methylthio-2-methylpyrazine 5-Methylthio-2-methylpyrazine
6-Methylthio-2-methylpyrazine
3208 
2290 
67952-65-2 
797 
JECFA specification (JECFA, 
2001c) 
6.3  
No safety concern a) 
Category B b) 
 
14.037 6,7-Dihydro-5-methyl-5H-
cyclopentapyrazine 
N
N
 
3306 
2314 
23747-48-0 
781 
JECFA specification (JECFA, 
2001c) 
3.9  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
14.043 2-Isobutyl-3-methoxypyrazine 
N
N
O
3132 
11338 
24683-00-9 
792 
JECFA specification (JECFA, 
2001c) 
1.6  
No safety concern a) 
 
 
14.044 2-Isobutyl-3-methylpyrazine N
N
3133 
 
13925-06-9 
773 
JECFA specification (JECFA, 
2001c) 
0.037  
No safety concern a) 
 
 
14.049 2-Acetyl-3-ethylpyrazine 
N
N
O
 
3250 
11293 
32974-92-8 
785 
JECFA specification (JECFA, 
2001c) 
0.73  
No safety concern a) 
 
 
14.050 2,3-Dimethylpyrazine N
N  
3271 
11323 
5910-89-4 
765 
JECFA specification (JECFA, 
2001c) 
14  
No safety concern a) 
 
 
14.053 Mercaptomethylpyrazine N
N
SH
3299 
11502 
59021-02-2 
794 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
14.054 Methoxypyrazine N
N
O
 
3302 
11347 
3149-28-8 
787 
JECFA specification (JECFA, 
2001c) 
3.0  
No safety concern a) 
 
 
14.055 2-Acetyl-3,5-
dimethylpyrazine N
N
O
N
N
O
 
3327 
11294 
54300-08-2 
786 
JECFA specification (JECFA, 
2001c) 
0.97  
No safety concern a) 
 
The JECFA evaluated 2-
acetyl-3,(5 or 6)-
dimethylpyrazine 
(mixture of two 
substancs with 
individual CASrn for 
each substance). 
Register CASrn to be 
changed/deleted. 
 
 
14.056 2,3-Diethyl-5-methylpyrazine 
N
N 3336 
11303 
18138-04-0 
777 
JECFA specification (JECFA, 
2001c) 
0.11  
No safety concern a) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
14.062 2-(sec-Butyl)-3-
methoxypyrazine 
N
N
O
 
3433 
11300 
24168-70-5 
791 
JECFA specification (JECFA, 
2001c) 
0.85  
No safety concern a) 
 
 
14.067 2-Methyl-3,5 or 6-
ethoxypyrazine 
N
N
N
N
N
N
O O
O
2-Methyl-3-ethoxypyrazine 2-Methyl-5-ethoxypyrazine
2-Methyl-6-ethoxypyrazine
3569 
11921 
32737-14-7 
793 
JECFA specification (JECFA, 
2001c) 
0.055  
No safety concern a) 
 
The JECFA evaluated 2-
methyl-3(or 5 or 6)-
ethoxypyrazine (mixture 
of three substancs with 
individual CASrn for 
each substance). 
Register CASrn to be 
changed/deleted. 
14.069 Cyclohexylmethylpyrazine N
N
3631 
 
28217-92-7 
783 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
14.077 2-Ethyl-(3,5 or 6)-
methoxypyrazine (85%) and 
2-Methyl-(3,5 or 6)-
methoxypyrazine (13%) 
N
N
O
N
N
O
(85%) (15%)
3280 
11329 
 
789 
JECFA specification (JECFA, 
2001c) 
1.3  
No safety concern a) 
 
 
14.082 2-Acetyl-3-methylpyrazine 
N
N
O
 
3964 
11296 
23787-80-6 
950 
JECFA specification (JECFA, 
2001c) 
0.1  
No safety concern a) 
 
 
14.095 3,5-Diethyl-2-methylpyrazine 
N
N 3916 
11305 
18138-05-1 
779 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
14.096 2,5-Diethyl-3-methylpyrazine 
N
N 3915 
11304 
32736-91-7 
778 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
14.098 6,7-Dihydro-2,3-dimethyl-5H-
cyclopentapyrazine 
N
N 3917 
11309 
38917-62-3 
782 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
14.100 3,(5- or 6-)-Dimethyl-2-
ethylpyrazine 
N
N
N
N
2-Ethyl-3,6-dimethylpyrazine2-Ethyl-3,5-dimethylpyrazine
3149 
727 
55031-15-7 
775 
JECFA specification (JECFA, 
2001c) 
38  
No safety concern a) 
 
JECFA CASrn: (13360-
65-1, 13925-07-0). 
14.114 2-Ethyl-6-methylpyrazine 
N
N 3919 
11331 
13925-03-6 
769 
JECFA specification (JECFA, 
2001c) 
0.37  
No safety concern a) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
14.121 2-Isopropyl-(3,5 or 6)-
methoxypyrazine 
N
N N
N
N
N
O O
O
2-Methoxy-3-isopropylpyrazine 2-Methoxy-5-isopropylpyrazine
2-Methoxy-6-isopropylpyrazine
3358 
11344 
93905-03-4 
790 
JECFA specification (JECFA, 
2001c) 
0.0012  
No safety concern a) 
 
 
14.123 Isopropylpyrazine 
N
N  
3940 
11343 
29460-90-0 
764 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern a) 
 
 
14.142 Propylpyrazine N
N
3961 
11362 
18138-03-9 
763 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern a) 
 
 
14.144 Pyrazine 
N
N
 
4015 
11363 
290-37-9 
951 
JECFA specification (JECFA, 
2001c) 
0.024  
No safety concern a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2002b). 
b) (CoE, 1992). 
ND)  No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 NORMAL AND MAXIMUM USE LEVELS 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
The “normal and maximum use levels” are provided by Industry for 21 of the candidate substances in the 
present flavouring group (EFFA, 2003q; EFFA, 2007a; EFFA, 2007e; EFFA, 2007f; Flavour Industry, 
2010m) (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.17Rev3 (EFFA, 
2003q; EFFA, 2007a; EFFA, 2007e; EFFA, 2007f; Flavour Industry, 2010m). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
14.052 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.081 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.083 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,5 
0,1 
0,5 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.084 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,5 
0,1 
0,5 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.086 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.087 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.091 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.097 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.099 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
- 
- 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.17Rev3 (EFFA, 
2003q; EFFA, 2007a; EFFA, 2007e; EFFA, 2007f; Flavour Industry, 2010m). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
14.101 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
- 
- 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.102 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.108 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
0,2 
1 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.113 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.122 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.127 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.129 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.139 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.147 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.148 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.161 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.170 1,72 
3,6 
- 
- 
1,1 
2,33 
- 
- 
- 
- 
2,92 
6 
- 
- 
3,13 
6 
2 
4 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1,93 
2,5 
0,3 
1 
- 
- 
- 
- 
II.2 MTAMDI CALCULATIONS 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
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• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
The mTAMDI values (see Table II.2.3) are presented for 21 of the substances in the present flavouring 
group, for which Industry has provided use and use levels (EFFA, 2003q; EFFA, 2007a; EFFA, 2007e; 
EFFA, 2007f; Flavour Industry, 2010m). The mTAMDI values are only given for highest reported normal 
use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
14.057 2-Isopropyl-3-methoxypyrazine  Class II 540 
14.081 5-Acetyl-2,3-dimethylpyrazine 270 Class II 540 
14.083 2-Acetyl-5-ethylpyrazine 270 Class II 540 
14.084 2-Acetyl-5-methylpyrazine 270 Class II 540 
14.086 2-Acetyl-6-ethylpyrazine 270 Class II 540 
14.087 2-Acetyl-6-methylpyrazine 270 Class II 540 
14.091 2-Butyl-3-methylpyrazine 270 Class II 540 
14.097 2,5-Diethylpyrazine 270 Class II 540 
14.099 6,7-Dihydro-5,7-dimethyl-5H-cyclopentapyrazine 190 Class II 540 
14.101 2,5-Dimethyl-3-isopropylpyrazine 190 Class II 540 
14.102 5,6-Dimethyldihydrocyclopentapyrazine 270 Class II 540 
14.111 3-Ethyl-2,5-dimethylpyrazine  Class II 540 
14.113 5-Ethyl-6,7-dihydro-5H-cyclopentapyrazine 270 Class II 540 
14.127 2-Methoxy-3-propylpyrazine 270 Class II 540 
14.129 2-Methyl-3-propylpyrazine 400 Class II 540 
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TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
14.148 5,6,7,8-Tetrahydro-5-methylquinoxaline 270 Class II 540 
14.161 6,7-Dihydro-2,5-dimethyl-5H-cyclopentapyrazine 400 Class II 540 
14.170 5-Ethyl-2,3-dimethyl pyrazine 1100 Class II 540 
14.052 Isopropenylpyrazine 400 Class II 540 
14.051 2,5 or 6-Methoxy-3-ethylpyrazine  Class II 540 
14.108 2,3-Dimethylquinoxaline 190 Class III 90 
14.109 2-Ethoxy-3-methylpyrazine  Class III 90 
14.112 2-Ethyl-3-methoxypyrazine  Class III 90 
14.126 2-Methoxy-3-methylpyrazine  Class III 90 
14.122 2-Isopropyl-3-methylthiopyrazine 270 Class III 90 
14.128 2-Methyl-3-methylthiopyrazine  Class III 90 
14.139 2-Methylquinoxaline 270 Class III 90 
14.147 Quinoxaline 270 Class III 90 
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ANNEX III: METABOLISM 
 III.1. Introduction 
This group of flavouring substances consists of 28 candidate substances, all of which contain a pyrazine ring. 
In 20 substances [FL-no: 14.051, 14.052, 14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 
14.101, 14.109, 14.111, 14.112, 14.122, 14.126, 14.127, 14.128, 14.129 and 14.170] only one heterocyclic 
ring is present. In five candidate substances a pyrazine ring is fused with either cyclopentane [FL-no: 14.099, 
14.102, 14.113 and 14.161] or cyclohexane [FL-no: 14.148]. All of these 25 substances have different 
substituents on the rings. In 16 of them, the substituents are simple alkyl chains and / or ketones. In nine, the 
substituents are, next to alkyl chains, either a methoxy- ([FL-no: 14.051, 14.057, 14.112, 14.126 and 
14.127], an ethoxy- [FL-no: 14.109], a thiomethyl- [FL-no: 14.122 and 14.128]) or an isopropenyl residue 
[FL-no: 14.052]. 
In the remaining three candidate substances the pyrazine ring is fused with benzene giving quinoxalines. In 
two of these substances [FL-no: 14.139 and 14.108] the pyrazine ring also bears one or two methyl 
substituents and in the third no substituents are present (quinoxaline [FL-no 14.147]).  
A group with 41 related supporting substances has been evaluated by the JECFA (JECFA, 2002a). 
 III.2. Absorption, Distribution and Elimination 
No pertinent absorption, distribution or elimination studies were found in the published or available 
unpublished literature for the candidate substances. Some information on supporting substances has been 
found, but the available information is still very limited.  
In rats, orally administered substituted pyrazines are absorbed from the gastrointestinal tract and excreted 
(Hawksworth and Scheline, 1975). Approximately 90 - 100 % of a 100 mg/kg dose of 2-methylpyrazine, 2,5-
dimethylpyrazine, 2,6-dimethylpyrazine or 2-methoxypyrazine administered to male Wistar rats by stomach 
tube was excreted in the urine as polar metabolites within 24 hours. Also, 50 % of the orally administered 
dose of 100 mg 2,3-dimethylpyrazine per kg was recovered in the urine within 24 hours (Hawksworth and 
Scheline, 1975). 
The supporting substance pyrazine [FL-no: 14.144] is a weak base with a pKa = 0.6 (Damani and Crooks, 
1982). At intestinal pH (pH = 5 - 7), absorption of weak amine bases such as pyrazine is optimal, because at 
these pHs such substances occur largely in the non-ionised state, which facilitates their absorption through 
the gastro-intestinal membranes (Hogben et al., 1959; Schranker et al., 1957). For the same reason it may be 
expected that the pyrazine derivatives in this group will be absorbed mainly after the passage through the 
stomach into the intestinal lumen. 
Groups of five anaesthetised male Sprague-Dawley rats were administered a single intravenous bolus dose of 
2, 5 or 10 mg tetramethylpyrazine/kg body weight (bw) through the femoral vein. Blood samples were 
withdrawn directly via heart puncture of the rat and collected from the same animals at 2.5, 5, 10, 15, 20, 30, 
45, 60, 90 and 120 minutes following administration to determine pharmacokinetic profiles in plasma. 
Distribution of tetramethylpyrazine was studied in various parts of the brain. It was determined that a two-
compartment open model best described the plasma concentration-time curve for all the dose levels. The 
plasma distribution half-life (t1/2,alpha) ranged from about 2.6 to 9.2 minutes and the elimination half-life (t1/2, 
beta) ranged from 20 to 28 minutes for the 2 and 10 mg tetramethylpyrazine/kg bw doses, respectively. Area 
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under the concentration curve (AUC) ranged from about 23 to 227 microg x min/ml and clearance (CL) 
ranged from 92 to 45 ml/min/kg for the 2 and 10 mg tetramethylpyrazine/kg bw doses, respectively. These 
results indicate that rapid distribution, elimination and clearance occur in rats within the tested concentration 
range of 2 - 10 mg tetramethylpyrazine/kg bw. Fifteen minutes after intravenous administration of 10 mg 
tetramethylpyrazine/kg bw, the cerebral cortex concentration and plasma concentration of 
tetramethylpyrazine were 1.45 ± 0.09 microg/g and 6.14 ± 0.38 microg/ml, respectively. There were no 
significant differences in tetramethylpyrazine concentration among the various regions of the brain (Liang et 
al., 1999). The data on plasma clearance also indicate that the kinetics of tetramethylpyrazine may not be 
linear with the dose level. 
An experimental design allowing simultaneous and continuous monitoring of tetramethylpyrazine 
concentrations in rat blood and brain was employed to study the distribution of an intravenously 
administered dose of 10 mg tetramethylpyrazine/kg bw. Microdialysis probes were inserted into the right 
jugular vein and striatum of four anaesthetised male Sprague-Dawley rats. Results indicate that both blood 
and brain pharmacokinetics of unbound tetramethylpyrazine fit best to a two-compartment model. The 
elimination half-life (t1/2,beta) of tetramethylpyrazine in rat blood and brain were about 28 and 53 minutes and 
the AUCs were about 82 and 185 microg x min/ml, respectively (Tsai and Liang, 2001). 
In conclusion: 
Very few data on absorption, distribution and elimination of the candidate or supporting substances are 
available. The available data indicate that the (weak) basic heterocyclic substances in this group may be well 
absorbed, mainly from the intestinal lumen, and may be rapidly excreted. 
 III.3. Metabolism 
III.3.1. Alkyl-, Alicyclic- and Alkylaryl-substituted Pyrazine Derivatives  
For two candidate substances [FL-no: 14.147 and 14.108], some information on metabolism has been 
submitted. Supportive data have also been taken from general reviews on metabolism and from submitted 
studies, in which biotransformation of substances with remote resemblance to the candidate substances has 
been described.  
In general, the biotransformation of the alkyl-, alicyclic-, and alkylaryl-substituted pyrazine derivatives is 
expected to occur via oxidation of the side-chains (see Figure III.1). For example, methyl-substituted 
pyrazines are oxidised to yield the corresponding pyrazine-carboxylic acids, which may be excreted as 
glycine conjugates (Hawksworth and Scheline, 1975). An alternative pathway for substituted pyrazines and 
primary pathway for pyrazine involves hydroxylation of the pyrazine ring (Hawksworth and Scheline, 1975; 
Whitehouse et al., 1987; Yamamoto et al., 1987a; Yamamoto et al., 1987b). For example, 2,5-
dimethylpyrazine and 2,6-dimethylpyrazine are oxidised in rats almost exclusively via their aliphatic side-
chains to carboxylic acid derivatives. Conversely, 2,3-dimethylpyrazine primarily undergoes ring 
hydroxylation, because side-chain oxidation is retarded (only 13 % of the administered dose oxidised) by the 
steric hindrance between the methyl groups (Hawksworth and Scheline, 1975). 
At least 89 % of a 100 mg/kg oral dose of 2-methylpyrazine, 2,5-dimethylpyrazine, or 2,6-dimethylpyrazine 
was metabolised in the rat by side-chain oxidation to yield the corresponding pyrazine-2-carboxylic acid 
derivative. The acids were mainly excreted unconjugated, although 9 and 14 % of the administered doses 
were excreted as the corresponding glycine conjugates for 2-methylpyrazine and 2,5-dimethylpyrazine, 
respectively. No glycine conjugation was observed with 2-methylpyrazine-6-carboxylic acid. 2,3-
Dimethylpyrazine was metabolised to 2-methylpyrazine-3-carboxylic acid (not conjugated with glycine) and 
2,3-dimethyl-5-hydroxypyrazine (in total 50 % of the dose). No N-oxygenation products could be detected in 
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the urine (Hawksworth and Scheline, 1975). Methyl side-chain oxidation to yield the corresponding alcohols 
has also been demonstrated for quinoxaline derivatives (Turesky et al., 1988; Knize et al., 1989; Sjödin et al., 
1989; Wallin et al., 1989). 
Alicyclic-substituted pyrazines, such as candidate substances 6,7-dihydro-5,7-dimethyl-5H-
cyclopentapyrazine [FL-no: 14.099], 5-ethyl-6,7-dihydro-5H-cyclopentapyrazine [FL-no: 14.113], 6,7-
dihydro-2,5-dimethyl-5H-cyclopentapyrazine [FL-no: 14.161] and 5,6,7,8-tetrahydro-5-methylquinoxaline 
[FL-no: 14.148], are expected to undergo side-chain oxidation similar to that previously described for alkyl 
substituted pyrazines (> C1), but no experimental evidence for this has been submitted. In addition, 
hydroxylation at various positions on the alicyclic ring is likely, based on general knowledge of metabolic 
conversion of alicyclic ring systems. The products of these oxidative metabolism reactions may be excreted 
unchanged or may be conjugated with glycine, glucuronic acid, or sulphate prior to excretion (Parkinson, 
1996a).  
Ring hydroxylation may be catalysed by molybdenum hydroxylases, e.g., xanthine oxidase and aldehyde 
oxidase, which are present in the cytosol of humans and other mammalian species, predominantly in the liver 
and small intestine. These enzymes catalyse ring hydroxylation of a wide range of endogenous and 
exogenous N-heterocycles bearing a substituent and/or a second fused ring. The molybdenum hydroxylases 
facilitate oxidation reactions involving nucleophilic attack by oxygen derived from water. Oxidation occurs 
at the most electropositive atom, which in N-heterocycles is generally the carbon adjacent to the ring 
nitrogen. The role of the molybdenum hydroxylases increases as the number of ring nitrogen atoms increase 
since each nitrogen activates the ring system toward nucleophilic attack. The oxidation action of the 
molybdenum hydroxylases is opposite to the microsomal monooxygenases (such as cytochrome-P450), 
which catalyse electrophilic attack by an oxygen atom derived from molecular oxygen (O2) (Beedham, 1985; 
Beedham, 1988; Parkinson, 1996a). Although substituted monocyclic pyrazines may be substrates for the 
molybdenum hydroxylases when other pathways are unfavourable, as indicated by the results of 
(Hawksworth and Scheline, 1975), bicyclic heterocycles are the preferred substrates of these enzymes 
(Stubley et al., 1979; Beedham, 1985; Beedham, 2002). 
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Figure III.1. Possible metabolic pathways of alkyl- and alkoxy-substituted pyrazine derivatives. Conjugates 
not shown. Excretion products are displayed in bold font. 
III.3.2. N-oxidation and N-methylation 
After in vivo administration of several methyl substituted pyrazine or pyridine derivatives to rats, no N-
oxygenation products could be detected in the urine (Hawksworth and Scheline, 1975).  
Generally, oxidation of ring nitrogen occurs in structures where the nitrogen atom has a nucleophilic 
character. N-oxidation of ring nitrogen has been reported in pyridine derivatives e.g. 3-acetyl pyridine is 
oxidised to give 3-acetyl pyridine N-oxide in in vivo and in vitro studies in rats and other laboratory animal 
species (Damani et al., 1980). The nucleophilicity of the ring nitrogen of pyrazine is much lower than in 
pyridine (pyrazine having a pKa of 0.6 in comparison with pyridine having a pKa of 5.17), suggesting that N-
oxidation in pyrazine may not occur. 
N-methylation of ring nitrogen in heterocyclic compounds has been reported, e.g. [2,6-14C]pyridine is 
methylated to N-methylpyridine in various mammals in vivo (D`Souza et al., 1980). 
However, similarly as above, methylation of ring nitrogen occurs in structures where the nitrogen atom has 
nuclephilic character. N-methylation of pyrazine derivatives therefore is unlikely to occur, in contrast to the 
situation with pyridine derivatives. 
Candidate substances  
Quinoxaline [FL-no: 14.147] 
Quinoxaline has been incubated in in vitro subcellular fractions to study the contribution of aldehyde oxidase 
(Mo-hydroxylase) and cytochrome P-450 in its metabolism. With aldehyde oxidase, formation of 2-
hydroxyquinoxaline could be determined (Km: 1.6 x 10-4 M) which could be further metabolised to 2,3-
dihydroxyquinoxaline. With cytochrome P-450 only a trace of a phenolic reaction product was obtained (not 
further characterised). As with quinoxaline, with several other mono-aza and di-aza bicyclic heterocyclic 
compounds (quinolines, phthalazine, quinazolines, cinnoline), similar phenolic conversions were observed. 
Except with cinnoline, in all cases with aldehyde oxidase, but not with cytochrome P-450, the hydroxylation 
occurred at the carbon adjacent to an N atom. The study indicates that the conversions by aldehyde oxidase 
may be more efficient than those by cytochrome P-450 (Stubley et al., 1977).  
Quinoxaline incubated in vitro with rabbit liver aldehyde oxidase is ring hydroxylated at a carbon atom 
adjacent to a ring nitrogen atom to yield 2-hydroxyquinoxaline and 2,3-dihydroxyquinoxaline. The apparent 
Michaelis-Menten constant of rabbit liver aldehyde oxidase for quinoxaline is Km = 1.76×10-4 (at pH = 7 and 
30°C). Incubation of quinoxaline with rat liver preparation yields qualitatively the same results as those 
using rabbit liver, but smaller amounts of the oxidation products are detected from rat liver incubations. 
Comparing the conversion of quinoxaline by rabbit and rat liver (10,000 g supernatants) during one hour 
incubations at 37°C, shows that the percentage conversion for rabbit is 6 and 5 % and for rat 4.4 and 4.5 % 
for 2-hydroxyquinoxaline and 2,3-dihydroxyquinoxaline, respectively (Stubley et al., 1979). 
2,3-Dimethylquinoxaline [FL-no: 14.108] 
Repeated administration of 2,3-dimethylquinoxaline [FL-no: 14.108] at a daily oral dose of 500 mg/kg bw 
for four days induces total hepatic cytochrome P-450 and cytochrome P-450-mediated biotransformations 
(aniline ring-hydroxylation, p-nitroanisole O-demethylation, aminopyrine N-demethylation, N-methylaniline 
N-demethylation) in female rat liver (Béraud et al., 1975). 
III.3.3. Pyrazine Derivatives Containing an Oxygenated Functional Group in the Side-chain  
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Candidate substances with an oxygenated functional group in the side chain are [FL-no: 14.051, 14.057, 
14.081, 14.083, 14.084, 14.086, 14.087, 14.109, 14.112, 14.126 and 14.127]. 
Rats were dosed with 100 mg/kg bw of 2-methoxypyrazine via gavage. Only 20 % of the urinary metabolites 
were identified as 2-hydroxypyrazine (i.e. the O-demethylated product). The other 80 % was one substance 
which was identified as a ring-hydroxylated 2-methoxypyrazine (Hawksworth and Scheline, 1975). Similar 
reactions can be expected to occur with candidate substances 2-, 5- or 6-methoxy-3-ethylpyrazine [FL-no: 
14.051],  2-isopropyl-3-methoxypyrazine [FL-no: 14.057], 2-ethyl-3-methoxypyrazine [FL-no: 14.112], 2-
methoxy-3-methylpyrazine [FL-no: 14.126], 2-methoxy-3-propylpyrazine  [FL-no: 14.127]. O-deethylation 
can be expected to some extent for 2-ethoxy-3-methylpyrazine [FL-no: 14.109]. 
Ring hydroxylation of the anti-tubercular agent, pyrazinamide, has been reported in vitro (Yamamoto et al., 
1987b) and in vivo (Whitehouse et al., 1987; Yamamoto et al., 1987a) in both humans and rats. Within 12 
hours after dosing, male rats with 150 mg pyrazinamide/kg bw by gavage, 60 % of the dose was excreted as 
hydrolysis products via the urine (25 % as 5-hydroxypyrazine-2-carboxylic acid and 35 % as pyrazine-2-
carboxylic acid). Parent compound and 5-hydroxypyrazinamide accounted for 14 and 3 % of the dose, 
respectively (Whitehouse et al., 1987). The same 5-hydroxylation products were detected in a urine sample 
of a man dosed with 12.5 mg pyrazinamide/kg bw. The hydroxylation of pyrazinamide and pyrazinoic acid 
in vitro to form 5-hydroxypyrazinamide and 5-hydroxypyrazine-2-carboxylic acid, respectively, occurred in 
the presence of xanthine oxidase-rich human liver cytosol (Yamamoto et al., 1987b). 
It has been demonstrated that in vitro and in vivo 3-acetylpyridine can be reduced at the carbonyl group to 
give 1-(3-pyridyl)-ethanol (Damani et al., 1980). Based on this observation, it may be expected that the 
structurally related candidate acetylated pyrazines, such as 2-acetyl-5-methylpyrazine [FL-no: 14.084], 2-
acetyl-6-methylpyrazine [FL-no: 14.087], 2-acetyl-5-ethylpyrazine [FL-no: 14.083], 2-acetyl-6-
ethylpyrazine [FL-no: 14.086], and 5-acetyl-2,3-dimethylpyrazine [FL-no: 14.081] may also be metabolised 
by reduction of the ketone functional group resulting in the formation of the corresponding secondary 
alcohol. Subsequently, the terminal methyl group in the acetyl-chain may be oxidised to yield the 
corresponding alpha-hydroxy-carboxylic acid. Alternatively, the terminal carbon atom of the acetyl side 
chain may be completely removed, which results in the formation of the corresponding pyrazine-carboxylic 
acid. Similar conversions have been demonstrated for acetophenone, which can be metabolised to mandelic 
acid or benzoic acid (Sullivan et al., 1976). 
Conclusion on metabolism of monocyclic or alicyclic- or aryl-bicyclic pyrazine derivatives with alkyl- or 
oxygenated functional group ring substituents: 
Very little information has been submitted to describe the metabolism of the pyrazines and alkyl-, aryl- or 
alicyclic-substituted pyrazines in this group of flavouring substances. The available information shows that 
pyrazine with a simple alkyl substituent may be oxidised at the side chain to give the corresponding 
carboxylic acid [FL-no: 14.097]. If such oxidations are not possible, e.g. due to steric hindrance, 
hydroxylation of the pyrazine ring may also occur [FL-no: 14.091, 14.101, 14.111 14.129 and 14.170]. The 
bicyclic pyrazine derivatives with an additional alicyclic or aryl ring substituent [FL-no: 14.099, 14.102, 
14.108, 14.113, 14.139, 14.147, 14.148 and 14.161] may be better substrates for ring hydroxylation, which 
seems to be carried out preferably by molybdenum hydroxylases. The candidate substances bearing a ketone 
ring substituent [FL-no: 14.081, 14.083, 14.084, 14.086 and 14.087] may be reduced at the carbonyl in the 
side chain to give the corresponding alcohol. The five monocyclic pyrazine derivatives with a methoxy side 
chain [FL-no: 14.051, 14.057, 14.112, 14.126 and 14.127] may also be expected to be metabolised via both 
ring hydroxylation and O-demethylation of the methoxy side chain. Accordingly, 2-ethoxy-3-methylpyrazine 
[FL-no: 14.109] may be expected to be metabolised via both ring hydroxylation and O-deethylation of the 
ethoxy side chain. With the resulting products of any of these flavouring substances, conjugation with 
glycine, sulphate or glucuronide may occur. In addition, with some related substances N-oxidation or N-
methylation have been observed, which may lead to biologically active metabolites. However, after in vivo 
administration of several methyl substituted pyrazine derivatives to rats, no N-oxidation products could be 
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detected in the urine. Additionally, the nucleophilicity of the pyrazine ring nitrogen is much lower than that 
of the pyridine ring nitrogen. It is concluded, therefore, that N-oxidation or N-methylation are unlikely to 
occur in the pyrazines.  
III.3.4. Pyrazine Derivatives Containing a Thiol or Sulphide Functional Group in the Side-chain 
The presence of sulphur in the side chain of pyrazines and alkylpyrazines provides a further metabolic 
option. The reactive lone pair of electrons on divalent sulphur in thiols and monosulphides permits rapid 
oxidation. Alkyl and aromatic sulphides, such as the candidate substances 2-isopropyl-3-methylthiopyrazine 
[FL-no: 14.122] and 2-methyl-3-methylthiopyrazine [FL-no: 14.128], can be oxidised to sulphoxides and 
then to sulphones (Hoodi and Damani, 1984; Nickson and Mitchell, 1994; Nickson et al., 1995). The 
oxidation to sulphoxides is catalysed by at least two enzyme systems, cytochrome P-450s and the flavin-
containing monooxygenases (FMO) (Cashman and Williams, 1990; Cashman et al., 1990; Cashman et al., 
1995a; Cashman et al., 1995b; Elfarra et al., 1995) and (Hoodi and Damani, 1984; Nnane and Damani, 1995; 
Rettie et al., 1990; Sadeque et al., 1992; Sadeque et al., 1995; Yoshihara and Tatsumi, 1990; Ziegler, 1980). 
The contribution of each system is highly dependent on molecular shape and nucleophilicity. For simple 
aliphatic, alicyclic and aromatic sulphides, oxidation is primarily catalysed by FMO and, to a lesser extent, 
by cytochrome P-450 (Hoodi and Damani, 1984). However, it is not clear which of these systems is of 
relevance for the sulphur containing candidate substances [FL-no: 14.122 and 14.128] in this group of 
flavouring substances. The FMO enzymes are easily saturated, already at very low sulphide concentrations 
(Ziegler, 1980). However, quantitative data to assess the actual role of FMOs in thioether sulphoxidation in 
vivo were not provided (Ziegler, 1980) but the observation might indicate that their role could be limited at 
higher levels of exposure. 
The final oxidation of the sulphoxide to the sulphone is an irreversible reaction (Damani, 1987; Williams et 
al., 1966). Essentially, all low molecular weight aliphatic and aromatic sulphones are metabolically stable. 
Hence, sulphoxides and sulphones are excreted in the urine of animals exposed to sulphides. 
As described above, the major reactions by which simple sulphides can be metabolised involve oxidation of 
the S to give a sulphoxide, which can be further converted to a sulphone. Alternatively, sulphides can 
undergo oxidation of the carbon alpha to the -S- resulting in the formation of an unstable hydroxyalkyl 
intermediate, which can be split to give an aldehyde and a free thiol. The aldehyde can be oxidised to its 
corresponding acid (Damani, 1987; Richardson et al., 1991). Similar reactions might occur with the 
candidate substances [FL-no: 14.122 and 14.128]. Thiols, such as the supporting substances 2-
(mercaptomethyl) pyrazine and 2-pyrazinylethanethiol, are very reactive substances. In vivo, they become 
even more reactive, mainly because most thiols exist in the ionised form at physiologic pH. Metabolic 
options for thiols include: oxidation to form unstable sulphenic acids (RSOH), which may be oxidised to 
sulphinic acid (RSO2H) and sulphonic acid (RSO3H); methylation to yield methyl sulphides, which then 
form sulphoxides and sulphones; reaction with physiologic thiols to form mixed disulphides and conjugation 
with glucuronic acid; or oxidation of the alpha-carbon, which results in desulphuration and the formation of 
an aldehyde (McBain and Menn, 1969; Dutton and Illing, 1972; Maiorino et al., 1989; Richardson et al., 
1991). 
Extensive discussions on the metabolism of sulphur-containing flavouring substances have been presented in 
FGE.08 and FGE.13. 
Candidate substances 
No pertinent metabolism studies were found in the published or available unpublished literature for the 
candidate substances. 
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 III.4. Summary and Conclusions 
This group of flavouring substances consists of 28 candidate substances, all of which contain a pyrazine ring. 
In 20 substances [FL-no: 14.051, 14.052, 14.057, 14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 
14.101, 14.109, 14.111, 14.112, 14.122, 14.126, 14.127, 14.128, 14.129 and 14.170] only one heterocyclic 
ring is present. In five candidate substances a pyrazine ring is fused with either cyclopentane [FL-no: 14.099, 
14.102, 14.113 and 14.161] or cyclohexane [FL-no: 14.148]. All of these 25 substances have different 
substituents on the rings. In 16 of them, the substituents are simple alkyl chains and / or ketones. In nine, the 
substituents are, next to alkyl chains, either a methoxy- ([FL-no: 14.051, 14.057, 14.112, 14.126 and 
14.127], an ethoxy- [FL-no: 14.109], a thiomethyl- [FL-no: 14.122 and 14.128]) or an isopropenyl residue 
[FL-no: 14.052]. 
In the remaining three candidate substances the pyrazine ring is fused with benzene giving quinoxalines. In 
two of the quinoxalines [FL-no 14.108 and 14.139] the pyrazine ring also bears one or two methyl 
substituents; in the third no substituents are present (quinoxaline; [FL-no 14.147]).  
A group with 41 related supporting substances has been evaluated by the JECFA (JECFA, 2002a). 
Very few data on absorption, distribution and elimination of the candidate or supporting flavouring 
substances are available. The available data indicate that the weak basic heterocyclic substances in this group 
may be well absorbed, mainly from the intestinal lumen, and may be rapidly excreted. 
Limited information has been submitted to describe the metabolism of the pyrazines and alkyl-, aryl- or 
alicyclic-substituted pyrazines in this group of flavouring substances. Almost all data available come from 
one paper (Hawksworth and Scheline, 1975) and a few review papers (Beedham, 1985; Beedham, 1988; 
Parkinson, 1996a). Additional information provided in other papers is supportive of the metabolic 
conversions that have been described, but of little quantitative relevance as they concern substances that are 
widely different from the candidate substances in this group and the supporting ones evaluated by the 
JECFA.  
Pyrazines with a simple alkyl substituent (e.g. [FL-no: 14.097]) may be expected to be oxidised at the side 
chain to give the corresponding carboxylic acid. If such oxidations are not possible, e.g. due to steric 
hindrance, hydroxylation of the pyrazine ring may also occur [FL-no: 14.091, 14.101, 14.111, 14.129 and 
14.170]. The bicyclic pyrazine derivatives with an additional alicyclic or aryl ring substituent [FL-no: 
14.099, 14.102, 14.108, 14.113, 14.139, 14.147, 14.148 and 14.161] may be better substrates for ring 
hydroxylation, which seems to be carried out preferably by molybdenum hydroxylases. The candidate 
substances bearing a ketone ring substituent [FL-no: 14.081, 14.083, 14.084, 14.086 and 14.087] may be 
reduced at the carbonyl in the side chain to give the corresponding alcohol. The five monocyclic pyrazine 
derivatives with a methoxy side chain [FL-no: 14.051, 14.057, 14.112, 14.126 and 14.127] may be expected 
to be metabolised via both ring hydroxylation and O-demethylation of the methoxy side chain. Accordingly, 
the monocyclic pyrazine derivatives with an ethoxy side chain, 2-ethoxy-3-methylpyrazine [FL-no: 14.109], 
may be expected to be metabolised via both ring hydroxylation and O-deethylation of the ethoxy side chain. 
With the resulting products of any of these flavouring substances, conjugation with glycine, sulphate or 
glucuronide may occur. In none of the studies, N-oxidation or N-methylation, which would lead to the 
formation of bioactive metabolites, has been observed. This is in agreement with the reactive properties of 
the heterocyclic nitrogen in the pyrazine moieties of the various substances studied. 
Two candidate substance in this group, 2-isopropyl-3-methylthiopyrazine [FL-no: 14.122] and 2-methyl-3-
methylthiopyrazine [FL-no: 14.128], are thioethers, which may be detoxified by formation of a sulphoxide 
and subsequently a sulphone, which are both stable and usually rapidly excreted. Alternatively, they may 
also be bioactivated via S-demethylation, resulting in the formation of a reactive free thiol. No data were 
provided to show that either route (sulphoxidation or S-demethylation) has prevalence over the other.  
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The limited amount of information on the metabolism of the substances in this flavouring group does not 
indicate that these substances will be metabolised to toxic products, except for the sulphur-containing 
flavouring substances [FL-no: 14.122 and 14.128], which may be converted to a reactive free thiol. For that 
reason, these two sulphur-containing pyrazine derivatives cannot be expected to be metabolised to innocuous 
products. Also [FL-no: 14.052], having a terminal double bond, which may be epoxidised giving rise to 
reactive metabolites cannot be expected to be metabolised to innocuous products.  
Originally (FGE.17), it was considered that the results from the genotoxicity studies with quinoxaline and 
derivatives [FL-no: 14.108, 14.139 and 14.147] indicate that these three may be metabolised into substances 
that are reactive to DNA. However, new data have become available for the structurally related substance, 5-
methylquinoxaline [FL-no: 14.028], considered in FGE.50Rev1. Based on these and other available data the 
Panel concluded that the in vitro genotoxicity alert could be ruled out for 5-methylquinoxaline [FL-no: 
14.028] (FGE.50Rev1) as well as for the structurally related substance 2,3-dimethylquinoxaline [FL-no: 
14.108] (FGE.17Rev2), but not for 2-methylquinoxaline  [FL-no: 14.139] and quinoxaline itself [FL-no: 
14.147].  
Therefore, based on the available data, the following substances in this group [FL-no: 14.051, 14.057, 
14.081, 14.083, 14.084, 14.086, 14.087, 14.091, 14.097, 14.099, 14.101, 14.102, 14.108, 14.109, 14.111, 
14.112, 14.113, 14.126, 14.127, 14.129, 14.148, 14.161 and 14.170] may be expected to be metabolised to 
innocuous products. Three substances [FL-no: 14.122, 14.128 and 14.052] cannot be anticipated to be 
metabolised to innocuous products. For the remaining two quinoxalines [FL-no: 14.139 and 14.147] a 
concern for genotoxicity has been identified (see also Section 8.4). 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for none of the candidate substances of the present flavouring group evaluation but for 18 supporting substances 
evaluated by the JECFA at the 57th meeting. 
Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(2-Methylpyrazine [14.027]) Rat NR Gavage 1800 (Moran et al., 1980)  
(2,3-Dimethylpyrazine [14.050]) Rat NR Gavage 613 (Moran et al., 1980)  
(2,5-Dimethylpyrazine [14.020]) Rat NR Gavage 1020 (Moran et al., 1980)  
(2,6-Dimethylpyrazine [14.121]) Rat NR Gavage 880 (Moran et al., 1980)  
(2-Ethyl-3-methylpyrazine [14.006]) Rat NR Gavage 600 (Moran et al., 1980)  
(2-Ethyl-5-methylpyrazine [14.017]) Rat NR Gavage 900 (Moran et al., 1980)  
(2,3,5-Trimethylpyrazine [14.019]) Rat NR Gavage 806 (Moran et al., 1980)  
(2-Ethyl-3, (5 or 6)-dimethylpyrazine [14.100]) Rat NR Gavage 456 (Moran et al., 1980)  
(2-Ethyl-3,5-dimethylpyrazine [14.024]) Rat M, F Gavage 504 (Posternak et al., 1975)  
(2,3,5,6-Tetramethylpyrazine [14.018]) Rat NR Gavage 1910 (Oser, 1969c)  
(2-Isobutyl-3-methoxypyrazine [14.043]) Mouse NR Gavage 2000 (Quest International, 1983a)  
Rat NR Gavage > 4000 (Roure Inc., 1974)  
(Acetylpyrazine [14.032]) Rat M, F Gavage > 3000 (Posternak et al., 1975)  
(2-(sec-Butyl)-3-methoxypyrazine [14.062]) Mouse NR Gavage 2000 (Quest International, 1983b)  
(Cyclohexylmethylpyrazine [14.069]) Mouse M, F Gavage 2673 (Babish, 1978a)  
(Mercaptomethylpyrazine [14.053]) Rat M, F Gavage 2100 (Burdock and Ford, 1990a)  
(Pyrazinylethanethiol [14.031]) Rat NR Gavage 158 (Posternak et al., 1975)  
(Pyrazinyl methyl sulfide [14.034]) Rat M, F Gavage 2500 (Posternak et al., 1975)  
(2-Methyl-3,5 or 6-methylthiopyrazine [14.035]) Rat NR Gavage 1970 (Posternak et al., 1975)  
1 Aspartic acid-fructose extracts were examined; 2,5-diethylpyrazine was one of 29 components identified in aspartic acid-fructose extract. 
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Subacute / Subchronic / Chronic / Carcinogenic toxicity data are available for none of the candidate substances of the present Flavouring Group Evaluation 
but for 17 supporting substances evaluated by the JECFA at the 57th meeting. 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duratio
n 
NOAEL 
(mg/kg bw/day) 
Reference Comments 
(2-Ethyl-3-methylpyrazine [14.006]) Rat; M, F 
32 
Diet  90 days M: 5.311 
F: 5.221 
(Posternak et al., 
1969) 
 
(2-Ethyl-5-methylpyrazine [14.017]) Rat; M, F 
30 
Diet  90 days M: 171 
F: 181,2 
(Oser, 1969d)  
(2,3-Diethylpyrazine [14.005]) Rat; M, F 
32 
Diet  90 days 1.751 (Posternak et al., 
1969) 
 
(2,3,5-Trimethylpyrazine [14.019]) Rat; M, F 
30 
Diet  90 days 181 (Oser, 1969e)  
(2-Ethyl-3, (5 or 6)-dimethylpyrazine 
[14.100]) 
Rat; M, F 
30 
Diet  90 days 181 (Oser, 1969f)  
(2-Ethyl-3,5-dimethylpyrazine 
[14.024]) 
Rat; M, F 
32 
Diet  84 days M: 12.71 
F: 12.31 
(Posternak et al., 
1975) 
 
(2,3,5,6-Tetramethylpyrazine [14.018]) Rat; M, F 
30 
Diet  90 days M: 501
F: 552 
(Oser, 1969e)  
(6,7-dihydro-5-Methyl-5H-
cyclopentapyrazine [14.037]) 
Rat; M 
10 
Diet  90 days 50 (Wheldon et al., 
1967) 
This study can not be evaluated as a complete report could not be provided. 
(5,6,7,8-Tetrahydroquinoxaline 
[14.015]) 
Rat; M, F 
30 
Diet  90 days M: 18.61
F: 19.31 
(Oser, 1970d)  
(Acetylpyrazine [14.032]) Rat; M, F 
32 
Diet  91 days M: 8.251
F: 8.151 
(Posternak et al., 
1975) 
 
(Methoxypyrazine [14.054]) Rat; M, F 
10-16 
Diet 20, 63, 200 mg/kg 91 days 20 (Osborne et al., 
1981) 
 
((2,5 or 6)-Methoxy-3- methylpyrazine 
[14.025]) 
Rat; M, F 
32 
Diet  90 days M: 451
F: 531 
(Posternak et al., 
1969) 
70-80 % 2-Methoxy-3-methylpyrazine,  
20-30 % (5 or 6)-Methoxy-3-methylpyrazine. 
(Cyclohexylmethylpyrazine [14.069]) Rat; M, F 
30 
Diet  90 days M: 0.441
F: 0.471 
(Babish, 1978b)  
(Pyrazinylethanethiol [14.031]) Rat; M, F 
32 
Diet  91 days M: 16.561
F: 16.301 
(Posternak et al., 
1975) 
 
(Pyrazinyl methyl sulphide [14.034]) Rat; M, F 
32 
Diet  91 days M: 1.661
F: 1.631 
(Posternak et al., 
1975) 
This study was not performed in accordance with modern guidelines. No treatment 
related effects were observed in either haematological examination, on blood urea 
determinations or in histilogical examination of 25 organs or tissues. A complete 
clinical biochemical examination was not performed. 
(2-Methyl-3,5 or 6-methylthiopyrazine 
[14.035]) 
Rat; M, F 
32 
Diet  91 days 41 (Posternak et al., 
1975) 
This study was not performed in accordance with modern guidelines. No treatment 
related effects were observed in either haematological examination, on blood urea 
determinations or in histilogical examination of 25 organs or tissues. A complete 
clinical biochemical examination was not performed. 
(5-Methylquinoxaline [14.028])  Rat; M, F 
32 
Diet  90 days 17.11 (Posternak et al., 
1969) 
 
1 This study was performed at a single dose level. 
2Growth rate and food utilisation efficiency effects were observed, but not accompanied by any evidence of pathology.  
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Developmental and reproductive toxicity data are available for none of the candidate substances of the present flavouring group evaluation but for four 
supporting substance evaluated by the JECFA at the 57th meeting. Supporting substance listed in brackets. 
Table IV.3: Developmental and Reproductive Toxicity Studies 
Chemical Name [FL-no]  Study type 
Durations  
Species/Se
x 
No / group 
Route  Dose levels NOAEL  (mg/kg bw/day), 
Including information of 
possible maternal toxicity 
Reference  Comments 
(2,3-Dimethylpyrazine [14.050]) Developmental toxicity 
2 weeks 
Rat; M 
5 – 7 
SC 0, 10, 30, 70, 100 1001 (Yamada et al., 1993) This study is considered of limited 
relevance, since the subcutaneous route of 
administration was used. 7 
(2,5-Dimethylpyrazine [14.020]) Developmental toxicity : 
To 1st oestrus; 1, 2 or 4 days 
Rat; F 
6 – 10 
SC 1002,3  
 
(Yamada et al., 1992) This study is considered of limited 
relevance, since the subcutaneous route of 
administration was used. 7 
Developmental toxicity : 
2 weeks 
Rat; M 
5 – 7 
SC 0, 10, 30, 70, 100 301 (Yamada et al., 1993) This study is considered of limited 
relevance, since the subcutaneous route of 
administration was used. 7 
Developmental toxicity : 
2 weeks 
Rat; M 
5 
SC 0, 10, 30, 70, 100, 
300 
306 
1005 
(Yamada et al., 1994) This study is considered of limited 
relevance, since the subcutaneous route of 
administration was used. 7 
(2,6-Dimethylpyrazine [14.021]) Developmental toxicity : 
2 weeks 
Rat; M 
5 - 7 
SC 0, 10, 30, 70, 100 701 (Yamada et al., 1993) This study is considered of limited 
relevance, since the subcutaneous route of 
administration was used. 7 
(2,3,5,6-Tetramethylpyrazine 
[14.018]) 
Reproductive/ Developmental 
Toxicity4 
Rat; F 
10 
Gavage 25, 125, 250 Maternal: 25 
Foetal: 250 
(Vollmuth et al., 1997)  
1Five to seven four-week old (juvenile) male Wistar rats/group were dosed subcutaneously once/day for two weeks.  
2Subcutaneous injections of female Wistar rats beginning at the age of three weeks with 100 mg/kg bw once daily until the first oestrus.  
32,5-Dimethylpyrazine pretreatment of seven week old females twice per day for one, two and four days prior to oestradiol injection.  
4Virgin rats administered 0, 25, 125, or 250 mg tetramethylpyrazine/kg body weight by gavage, seven days prior to and through cohabitation, gestation, delivery, and a four-day postparturition period.  
5Five six-week old (mature) male Wistar rats/group were dosed subcutaneously once/day for two weeks at doses of 100 or 300 mg/kg bw. 
6 Five four-week old (juvenile) male Wistar rats/group were dosed subcutanously once/day for two weeks at doses of 10, 30, 70, 100, or 300 mg/kg bw. 
7It was concluded that the findings were of little relevance for the risk assessment of pyrazines as flavourings. 
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In vitro mutagenicity/genotoxicity data are available for three candidate substances of the present flavouring group evaluation and for 11 supporting 
substances evaluated by the JECFA at the 57th meeting. Supporting substances are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(Pyrazine [14.144]) 
  
Ames test S. typhimurium 
TA98; TA100; TA102 
64000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
64000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
Not reported Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound within a large study, details are reported for positive compounds only.  
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Ames test S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538 
10000 µg/ml Negative1, 2 (Fung et al., 1988) Valid study in accordancce with OECD guideline 471. 
 
Mutation assay S. cerevisiae 
Strain D5 
60000 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
Aberration assay 
Chinese hamster 
ovary cells 
10000 µg/ml 
2500 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
Mouse lymphoma 
mutagenesis assay 
mouse lymphocytes  
L5178Y TK+/- 
10000 µg/ml Negative1 (Fung et al., 1988) Study in accordancce with former OECD guideline 476 (1983); colonies were not 
sized and results were not confirmed in a second study as requested by the OECD 
guideline in force. Therefore, chromosomal aberrations effects could not be ruled 
out.   
(2-Methylpyrazine [14.027]) Ames test S. typhimurium 
TA98; TA100; TA102 
94000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
94000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
Not reported Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound of a large study, details are reported for positive compounds only. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
67500 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
Aberration assay 
Chinese hamster 
ovary cells 
40000 µg/ml 
20000 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(Ethylpyrazine [14.022]) Ames test S. typhimurium 
TA98; TA100; TA102 
97200 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97200 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
67500 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
Aberration assay 
Chinese hamster 
ovary cells 
5000 µg/ml 
2500 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(2,3-Dimethylpyrazine [14.050]) Ames test S. typhimurium 
TA98; TA100; TA102 
97200 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97200 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains. only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
NR Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound within a large study, details are reported for positive compounds only. 
(2,5-Dimethylpyrazine [14.020]) Ames test S. typhimurium 97200 µg/plate Negative1 (Aeschbacher et al., 97200 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
TA98; TA100; TA102 1989) although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
Not reported Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound of a large study, details are reported for positive compounds only. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
200000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
135000 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
aberration assay 
Chinese hamster 
ovary cells 
40000 µg/ml 
20000 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(2,6-Dimethylpyrazine [14.021]) Ames test S. typhimurium 
TA98; TA100; TA102 
54000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
54000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
10800 Negative4 (Lee et al., 1994a) Well conducted study, valid although not in accordance with OECD guideline 
471: two S. typhimurium strains only. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
33800 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
aberration assay 
Chinese hamster 
ovary cells 
10000 µg/ml 
2500 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(2,3-Diethylpyrazine [14.005]) Ames test S. typhimurium 
TA98; TA100; TA102 
109000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
109000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
(2,3,5-Trimethylpyrazine [14.019]) Ames test S. typhimurium 
TA98; TA100; TA102 
97735 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97735 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only. 
((2,5 or 6)-Methoxy-3- 
methylpyrazine [14.025]) 
Ames test S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538 
3600 µg/plate Negative1 (Wild et al., 1983) Well conducted study, valid although not in accordance with OECD guideline 
471:  test concentrations not reported. 
(Pyrazinylethanethiol [14.031]) Ames test S. typhimurium 
TA97; TA98; TA100; TA1535 
NR Negative1 (Zeiger and Margolin, 
2000) 
Well conducted study, valid although not in accordance with OECD guideline 
471: report does not give test concentrations, four test concentarions. 
Quinoxaline [14.147] Ames test S. typhimurium 
TA98; TA100 
NR Negative3 (Beutin et al., 1981) TA98 ; TA100: results presented in detail, without metabolic activation.  
TA1535,TA1537,TA1538: results incl. metabolic activation are mentioned in text 
(negative), but no data given. Not in accordance with OECD guideline 471.  
Ames test S. typhimurium 
TA98; TA100; TA102 
0.35 mmol Negative3, 5 (Aeschbacher et al., 
1989) 
0.35 mmol: highest non-bactericdial dose. Well conducted study, valid although 
not in accordance with OECD guideline 471: three S. typhimurium strains only, 
dose range but not individual doses reported. 
Modified Ames 
test 
S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538; 
G46; C3076; D3052 
E. coli 
WP2; WP2uvrA- 
NR Negative3 (McMahon et al., 1979) Review, of limited value (concentrations tested not reported).  
Ames test 
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538 
10000 µg/plate Negative3 (San, 1995) Valid study in accordancce with OECD guideline 471. 
DNA Polymerase 
deficiency assay 
E. coli NR Negative3 (Rosenkranz and Leifer, 
1980) 
Review, of limited value (concentrations tested not reported; without metabolic 
activation). 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
SOS 
Chromosome test 
E. coli 
PQ37 
NR Negative1 (Beutin et al., 1981)  
 Mouse lymphoma 
mutagenesis assay 
L5178Y TK+/- 
mouse lymphocytes 
(with S9) 20 – 
250 
(without S9) 100 
– 1500 microg/ml 
 
Positive6 
Weakly 
Positive3 
(National Cancer 
Institute, 1998) 
Valid study in accordancce with OECD guideline 476.  
 
2-Methylquinoxaline [14.139] Ames test S. typhimurium 
TA98; TA100 
500 µg/plate Positive1 (Hashimoto et al., 1979) Well conducted study, valid although not in accordance with OECD guideline 
471: two S. typhimurium strains only, highest dose but not individual doses 
reported. 
Positive only in TA98 and T100 with metabolic activation.  
Ames test S. typhimurium 
TA98; TA100; TA102 
0.007 - 700 
µmol/plate 
(equal to 0.001 – 
100 mg/plate) 
Negative1, 7 (Aeschbacher et al., 
1989) 
0.7 mmol: highest non-bactericidal dose. Well conducted study (valid), but not in 
accordance with OECD guideline 471: three S. typhimurium strains only, dose 
range but not individual doses reported. 
2,3-Dimethylquinoxaline [14.108] Ames test S. typhimurium 
TA98; TA100; TA1535; 
2500 µg/plate Negative6 (Anderson and Styles, 
1978) 
Well conducted study, valid although not in accordance with OECD guideline 
471 (with S9 metabolic activation only). 
Ames test S. typhimurium 
TA100 
NR Negative6 (Epler et al., 1978) Review, no detailed information on test conditions incl.concentration. Authors 
pointed out the unanswered question whether the testing of negative compounds 
can sensibly be terminated (in 1978).  
 Ames test S. typhimurium 
TA98; TA100 
NR Negative1 (Hashimoto et al., 1979) Validity cannot be evaluated. Concentrations not reported. Results not reported in 
detail. 
(5-Methylquinoxaline [14.028]) Reverse mutation S. typhimurium TA 98, TA100, TA1535, 
TA1537 and E. coli WP2 uvrA 
Up to 5000 
microgram/plate 
Negative1 (Ogura and Wakamatsu, 
2004) 
Valid. GLP-study in compliance with OECD 471 (except that no justification was 
provided for the use of duplicate instead of triplicate plating). 
Reverse mutation E.coli strain WP2 uvrA Up to 5000 
microgram/plate 
Negative1 (Ogura and Wakamatsu, 
2004) 
Valid. GLP-study in compliance with OECD 471 (except that no justification was 
provided for the use of duplicate instead of triplicate plating). 
Chromosomal 
aberration assay 
Chinese hamster lung-derived CHL/IU 
cells 
320, 480, 720 
microgram/ml 
72, 228, 720 
microgram/ml 
Negative3 
 
Positive6 
(Ajimu and Kawaguchi, 
2004a) 
Valid. GLP-study mainly in compliance with OECD 473 (duration of exposure 
not clearly reported). The authors noted in the discussion section that cytotoxicty 
was observed in the form of decreased cell viability and reproductive rate. 
However, it is not clear if one or two parameters for cytotoxicity were measured. 
The percentage of “cell productivity” (the cell number was measured and 
expressed as relative growth rate compared to negative control) was reported. 
According to the authors, there was a clear evidence of cytotoxicty in the form of 
decreased cell viability and reproductive rate at concentrations where 
chromosomal aberrations were observed. However, the results presented in tables 
demonstrate that 30 and 66 % of cell with chromosomal aberrations were induced 
at the limit of exessive cytotoxicty (54 and 46 % of relative growth) in the 
preliminary test (in which 50 cells per slide were scored) at 180 and 360 µg/mL in 
the presence of S9, respectively. In the main test, the percentage of cells with 
chromosomal aberrations in the presence of S9 was 2.0, 2.5, 6.5 and 57.5 at 0, 72, 
228 and 720 µg/mL, respectively, which was accompanied by 100, 90, 85 and 46 
% relative growth, respectively. 
NR: Not reported. 
1 With and without S9 metabolic activation.  
2 Metabolic activation was provided with both rat and hamster liver S9 mix.  
3 Without S9 metabolic activation.  
4 Results were negative in TA100 with and without S9 metabolic activation; however, in TA98 the results were negative and positive with and without S9 metabolic activation, respectively.  
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5 Results were negative in TA100 with and without S9 metabolic activation. Weak results were noted in TA98 and TA102 with S9 metabolic activation. These changes may be related to the heat production products of the Maillard reaction in the 
presence of creatinine.  
6 With S9 metabolic activation.  
7 Weak results were noted in all strains with S9 metabolic activation. (the number of revertants was increased up to 1.3-fold compared to control). According to the authors (Aeschbacher et al., 1989), these changes may be related to the heat 
production products of the Maillard reaction in the presence of creatinine. 
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In vivo mutagenicity/genotoxicity data are available for one candidate substance of the present flavouring group evaluation from chemical group 24 and for 
two supporting substances evaluated by the JECFA at the 57th meeting. The supporting substance is listed in brackets.  
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
(2,5 or 6-Methoxy-3- methylpyrazine [14.025]) Basc test D. 
melangaster 
 10 mM Negative (Wild et al., 1983) Limited relevance for risk assessment as the test is not in a mammalian 
system and the test is not used routinely.  
Micronucleus assay Mouse  87, 174, 248 
mg/kg 
Negative (Wild et al., 1983) Study design does not meet the criteria of current guidelines (PCE/NCE 
ratio was not reported, thus it is not clear if the test substance reached 
the bone marrow). Not in accordance with OECD guideline 474 
(1983/1997). 
Quinoxaline [14.147] Sperm head abnormality 
test 
Mouse I.P. 2500 mg/kg  Negative (Topham, 1980) Sperm head abnormality test does not make use of a genetic endpoint. 
(5-Methylquinoxaline [14.028]) Micronucleus assay Mouse Gavage 125, 250 and 
500 mg/kg/day 
Negative (Ajimu and Kawaguchi, 
2004b) 
Valid. GLP-study mainly in compliance with OECD 474 (only 5 male 
mice per group instead of 5 males and 5 females).  
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ABBREVIATIONS 
ADI  Acceptable Daily Intake  
AUC  Area Under Curve 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells)´ 
CL Clearance 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
FMO  Flavin-containing Monooxygenase 
DLP  Dood Laboratory Practice 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MNPCE Micronucleated polychromatic erythrocytes 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
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PCE  Polychromatic erythrocytes 
SC  Subcutaneous 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
